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INTRODUCTION 
 
The International Association for the Study of Pain defines pain as “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage or described in terms of such damage”1. Pain management is an 
essential component of care provided by paediatric anesthesiologists.  
Regional anaesthesia plays an important role in providing pain relief both in 
the intra-operative and postoperative periods in paediatrics. Caudal epidural 
anaesthesia is the most commonly practiced regional technique in children. The 
practice of placing a caudal block before incision in general anaesthesia results in 
reduced inhaled concentrations of volatile anesthetics intraoperatively
2
. Local 
anaesthetics are commonly used either alone or with additives through the caudal 
route but the motor block produced may be a cause of distress to children in the 
postoperative period 
3
. 
             Caudal block is usually placed after the induction of general anesthesia and 
is used as an adjunct to intraoperative anesthesia as well as postoperative analgesia 
in children undergoing surgical procedures below the level of the umbilicus
4
. 
Caudal analgesia can reduce the amount of inhaled and IV anesthetic 
administration, attenuates the stress response to surgery, facilitates a rapid, smooth 
recovery, and provides good immediate postoperative analgesia. 
          Bupivacaine is a long-acting amide local anaesthetic that has provided 
reliable anaesthesia and analgesia with differential motor&sensory blockade for 
more than 40 years 
5,6
. But, toxicity due to accidental intravascular or intrathecal 
injections of bupivacaine resulting in severe neurological, cardiovascular 
depression even leading to death prompted studies on the mechanism of the 
cardiotoxic effects of local anaesthetics and search for drugs with less 
cardiotoxicity
7,8
.Bupivacaine is commercially available as racemic mixture of R- 
and S- enantiomers. It has been shown that block of the inactivated state of the 
cardiac sodium and potassium channels is stereoselective, with R-bupivacaine 
being more potent than S-bupivacaine 
9
. 
           Ropivacaine, a long-acting amide local anesthetic related structurally to 
bupivacaine, has been used for pediatric caudal anesthesia. It provides pain relief 
with less motor blockade. Literature suggests that ropivacaine is less cardiotoxic 
than bupivacaine, hence ropivacaine may be a more suitable agent for caudal 
epidural analgesia especially in day care surgery
10
. The sensory block provided by 
ropivacaine is similar to that produced by an equivalent dose of  bupivacaine in 
extradural and peripheral nerve block whereas the motorblock produced by 
ropivacaine is slower in onset, less intense and shorter in duration than 
bupivacaine
11
. 
           These features combined with decreased cardiovascular and neurological 
toxicity make ropivacaine very useful in paediatric practice especially for day case 
surgery which is increasing in frequency. Hence,this study was undertaken to 
compare the effectiveness of ropivacaine  with  bupivacaine  for  caudal  
anaesthesia  in children. 
                                
                   
                                   
                                    
AIM OF THE STUDY 
 
To  assess  the       - Safety,  
                              - Efficacy,  
                              - Onset and Duration of analgesia 
 of 0.25% Bupivacaine and 0.2% Ropivacaine when equal volumes 
of Dexmedetomidine is added as an adjuvant in Paediatric caudal 
block.  
 
 
 
         
                            
 
 
 
 
 
ANATOMY OF CAUDAL EPIDURAL SPACE 
                     The key to success in any regional technique is a clear understanding 
of the normal anatomy of the region and an appreciation of the variations that may 
be encountered normally. This is possible more relevant to the success of the caudal 
blockade than to other techniques. 
Anatomy of Sacrum 
Sacrum is a large triangular bone formed by the fusion of five sacral 
vertebrae articulating above with 5th lumbar and below with the coccyx. The base 
above has median and lateral positions. The median part represents the body of the 
1st sacral vertebra and lateral portions, known as the alae represent fused costal and 
transverse elements. 
 
The anterior surface is concave and ridged at the sites of fusion between the 
five sacral vertebrae. Lateral to the anterior sacral foramen through which the 
primary rami of the first four sacral nerves pass. The posterior surface is convex 
and in the midline runs a bony ridge called the median sacral crest with three or 
four, but commonly four, variably prominent tubercles, representing rudimentary 
spinous processes. The lamina of 5th and sometimes the 4th sacral vertebra fails to 
fuse in the midline. The deficiency thus formed is known as “SACRAL HIATUS”. 
The lateral margins of this each space bear a prominence. “SACRAL 
CORNUA”which represents the inferior articular processes of 5th sacral vertebra. 
Sacral Canal  
 
  
It is a prismatic cavity running throughout the length of the bone and following its 
curves. Superiorly it is triangular in section and is continuous with lumbar epidural 
space.Its lower extremity is the sacral hiatus which closed by posterior 
sacrococcygeal membrane which is a continuum of ligamentum flavum. Fibrous 
bands may be present in the canal and divide the epidural space into loculi which 
prevent the spread of solution and these may account for occasional incomplete 
anaesthesia. 
 
 
 
Contents of Sacral Canal: 
1. The dural sac extends and ends at the lower end of 2nd sacral vertebra on a line 
joining the posterior superior iliac spine from the age of 2 years, compared to S3 – 
S4 at birth. 
2. Sacral and coccygeal nerve roots with their dorsal root ganglia. 
3. The filum terminale which is the continuation of piamater, a non nervous 
terminal filament of the spinal cord. 
4. Epidural plexus of veins formed by the lower end of vertebral veins, a part of 
valveless internal vertebral venous plexus. 
5. Loose areolar and fatty tissue is denser in males than in females. In infants, fat is 
gelatinous spongy and few connective tissues facilitates a uniform and rapid spread 
of local analgesic solutions. In adults it is a closed fibrous mesh texture.It has been 
suggested that this difference gives rise to the predictability of caudal local 
anaesthetic spread in children and its unpredictability in adults. 
Sacral Hiatus: 
This is a triangular opening in the posterior wall of the sacrum resulting 
from the failure of fusion of the laminae of the 5th sacral vertebra and usually part 
of S4. It’s apex is at the level of the spine of 4th sacral vertebra. 
The hiatus is covered by sacrococcygeal membrane and pierced by the 
coccygeal nerves 5th sacral nerve. The posterior sacrococcygeal membrane may be 
ossified in elderly subjects and making the introduction of the caudal needle almost 
impossible. The distance between the sacral hiatus and dural sac may be as short as 
10 mm in a neonate. In the presence of certain sacral malformations, this distance 
might be less and the dural sac can project even up to the level of sacral hiatus. 
After the age of 6-7 years, epidural fat gets denser and is surrounded by fibrous 
strands, thus reducing the uniform spread of the local analgesic solutions.  
The important characteristic of the caudal epidural space is that it 
communicates freely with the perineural spaces surrounding the spinal nerves of 
the lumbosacral trunk. This has several implications. Local analgesic solutions 
injected into the caudal space diffuse widely into the perineural spaces, thereby 
improving the quality of the neural block even when dilute local analgesic solutions 
are used. Such a leakage into the perineural spaces also leads to an increase in the 
required volume of local anaesthetic. Spaces are open in children and explain why 
larger volumes are required in children as compared to adults. 
The sacrum is cartilaginous in neonates and infants and its ossification is 
completed between 25 - 30 years of age. In the neonate, the long axis of the sacrum 
forms an acute angle with the long axis of the coccyx, thereby making it relatively 
easy to palpate the sacral cornua and hiatus. As the age increases, the 
sacrococcygeal angle also increases. Thus closing the sacral hiatus makes a caudal 
anaesthetic technique difficult after the age of 7 years. When local anaesthetic 
solution is injected into the sacral canal, it ascends upwards in the sacral epidural 
space for a distance proportional to the volume of solution, force of injection, 
amount of leakage through the eight sacral foraminae and the consistency of the 
connective tissue in the space. Favourable anatomical differences in paediatric age 
group against the adult are, 
1) The dorsal aspect of the sacrum is almost flat in young infants and the sacral 
hiatus is identified by the easily palpable sacral cornua which is larger. 
2) The epidural fat is very loose in infants and children. So the predictability of 
caudal local anesthetic spread is possible in the paediatric age group. 
3) The subcutaneous tissues are also less densely packed in infants and children 
that make the palpation of landmark easier. 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CAUDAL ANAESTHESIA 
Selection of Equipment 
Reliability of the technique and the incidence of complications largely depend on 
the characteristics of the needle used. 
              The four important characteristics of the needle 
                    • Bevel 
                    • Internal and external diameter 
                    • Its length 
                    • Presence of a stylet 
Sharp bevelled Needle: 
Advantage: Traverse easily through the tissues 
Disadvantages: 
        1. Characteristic “give way” when sacrococcygeal membrane is   
            punctured may not be clearly felt with sharp needles. 
       2. Sharp needles have long bevel advanced further into the epidural   
           space so that it lies entirely within it. 
      3. Cartilaginous sacrum can be easily traversed by a sharp and long  
          bevelled needle leading to rectal puncture or iliac vessel puncture.  Straight 
tipped needle with a bevel of 45 – 60 degree is ideal. 
Diameter: 
            Small needles may bend & break during procedure. Thin needles may “give 
way”. Puncturing cartilaginous structures give rise to inadvertent intraosseous 
injection which produces effect similar to I.V. Injection. It mayenter pelvic viscera 
and cause damage. 21 to 23 Gauge is ideal because it is rigid and large enough to 
allow reflux of blood or cerebrospinal fluid. 
Length: 
           Proximity of the dural sac makes it dangerous to use very long needles. 
Distance from the skin to the epidural space is almost always less than 20mm even 
in adults. So it is not advisable to use a needle longer than 30 mm. If needle with a 
stylet is used, it prevents the formation of an epidermoid tumour due to skin tag. 
Epidural needle with 20 to 22 gauges are employed when one intends to use an 
epidural catheter via caudal route to achieve anaesthesia at higher level after 
radiographic conformation. 
Factors determining the quality of caudal block: 
    • Intensity of block achieved by type and concentration of   local anaesthetic. 
   • Height of block which depends on the volume injected 
Methods for determination of the volume of Local anaesthetic: 
Formula based on weight or age: 
Armitage(1979) formula 
27– Practically  easy  to apply 
                 High sacral - 0.5 ml / kg 
                 High lumbar - 1 ml/kg 
                 Thoracic level - 1.25 ml / kg 
Sclhute – Steinberg formula (up to 8-12 years)28(1977) 
            0.1ml / segment / year 
           < 7 years – weight best predictor  
           Volume required in ml = 0.65 x number of segments to be blocked  
                                                   x body weight (kg)  
 
Spiegal Formula 
29
: 
              Total volume of injection (ml) = 4 + (D-15) / 2 Where D is the distance 
separating the sacral hiatus from the spinous process of 7th cervical vertebra. 
Modified spiegal formula: 
             Volume of injection (ml) = 4 + (D-13) / 2 
             Despite larger volumes of local anaesthetic used in children as compared to 
adults, peak plasma levels of the local anaesthetics in children remain far below the 
toxic levels in adults.  
            As the child grows, space becomes less compliant and large volume can 
cause higher spread of solution and thus increasing the concentration of local 
anaesthetics in the CSF. 
Satayoshi formula:
30 
         V= D-13 Where V is the volume of local anesthetic in milliliters 
And  D is the distance from C7 to the sacral hiatus in centimeters. 
Takasaki formula:
31 
 
        Volume in ml / spinal segment = 0.056 ( weight in kg)- 0.002 
Patient position: 
         Three positions are available for caudal anesthesia; 
                    1. Prone position - Most often chosen in adults 
                   2. Lateral decubitus position – This is the most commonly used  
                       position in paediatric age group. 
                  3. Knee-chest position – This is infrequently used. 
                 The lateral decubitus position is used in children because it is easier to 
maintain a patent airway in this position than in the prone position and the 
landmarks are more easily palpable than in adults. 
Anatomicallandmarks: 
 
 
 
 
    Classically hiatus is described as the inferior apex of an equilateral triangle 
formed by joining the two posterior superior iliac spines and the tip of coccyx. 
                   Intergluteal fold is not an ideal landmark because it will not always 
correspond to the midline. When the left forefinger is placed in the coccyx tip, then 
the hiatus corresponds to the second crease of the finger. Palpation of this 
membrane gives a characteristic feel of a membrane under tension similar to that of 
a fontanelle. The point of puncture is at the midpoint of this triangular space. 
Technique: 
              Prepare area with an antiseptic solution  
              Sterile drapes are placed around the site  
              Puncture the skin with the needle perpendicular and bevel parallel to the 
long fibres of the sacrococcygeal membrane.  
Once the needle crosses the sacrococcygeal membrane, a “give” is felt after which 
make an angle of 20-30 degree with the skin. This is done to prevent the needle 
hitching against the anterior aspect of the sacrum.Advance the needle 2-3 mm, not 
more than the line joining the posterior superior iliac spines as to ensure that the 
entire bevel is within the sacral canal. 
Confirmation of space: 
Swoosh test :If the needle is correctly positioned in the caudal space, while 
injecting local anaesthetics, Swoosh sound is heard at a site just proximal to 
hiatus,It is useful in children to avoid air injection which cause a patchy block and a 
rare complication of pneumocephalus if injected in large amount of air. Venous air 
embolism can also occur. Other techniques commonly used to identify the space 
are: 
                   o Easy injection of drug 
                   o No resistance to injection 
                   o No subcutaneous bulge 
Injection of Drug: 
After a gentle aspiration, the drug should be injected over a period of 60-90 
seconds, irrespective of the volume injected (0.023 ml – 0.033 ml / sec). Syringe 
should be repeatedly aspirated during the course of injection. Any change in blood 
pressure and heart rate should be monitored while injection. Faster injection cause 
increased cephalad spread resulting in a high block and respiratory problems. In 
accidental intravascular injection, fast injection will cause rapid increase in peak 
plasma concentration. On the other hand, too slow an injection increase the chances 
of lateralization of the block or a lower level of anesthesia since the drug tends to 
leak through the foramina or increase the risk of needle displacement. 
Indications: 
It is ideal for both elective and emergency lower abdominal and lower limb 
surgeries 
Emergency : testicular torsion, strangulated hernia repair, paraphimosis, wound 
debridement of pelvis and lower limbs 
Elective : Usually combined with light general anaesthesia 
Repair of inguinal hernia, umbilical hernia and hydrocele 
Orchidopexy, anorectal and genito urinary surgery ,Pelvic, Hip and Lower 
extremity surgeries,Phimosis 
Contraindications: 
           Local skin infection 
           Pilonidal sinus near hiatus 
           Major sacral malformation – Meningomyelocele 
           Meningitis 
           Spinabifida occulta – Not a contraindication 
Caution: 
          Hydrocephalus 
          Convulsion disorders 
          Vertebral osteo synthesis 
Complications: 
Due to errors of needle position and puncture technique: 
       1. Subcutaneous injection 
       2. Puncturing sacral foramen – needle may enter the 3rd or 4th   
           foramen, block of only the sacral root in question. 
      3. Vascular puncture – By using short bevelled needle, the incidence  
          can be reduced. 
      4. Dural puncture - If dura is punctured withdraw the needle  
          immediately,  then 2nd caudal can be attempted with caution of  
          injecting the drug under low pressure. 
      5. Rectal injection or intra osseous injection can occur. 
Puncture complications are more common in difficult caudal. 
Complications due to errors of injection: 
1. Intravascular injection; Since epidural veins are valveless, the intra  
    vascular injection is immediately followed by convulsions, arrythmias,  
    hypotension and respiratory depression. 
2. Subarachnoid space injection: It leads to total spinal anaesthesia. 
3. Hemodynamic problems: This was rare in children below 8 years, in  
    the absence of intravenous or subarachnoid injection. 
 
4. Complete or partial failure of the block: Complete failure of block is  
    more common after 7years of age. 
Success rate increases and failure rate decreases with experience, but the failure 
rate will never be zero even in experienced hands. 
Neurologic complications: 
Urinary retention is more common if are narcotics given via caudal route. The 
first act of micturition may be delayed but not troublesome.  
Loss of consciousness is due to very rapid injection of a large volume of local 
anaesthetics. 
Nerve lesions are rarest complication 
 
 
      
 
PHARMACOLOGY  OF  DEXMEDETOMIDINE
32 
 
                           
           Dexmedetomidine is an α2-agonist that received FDA approval in 1999 for 
use as a short-term (less than 24 h) sedative analgesic in the intensive care unit. 
Clonidine, the prototype of α2-agonist, is widely used as an adjunct to anesthesia 
and pain medicine; however, it has been little used as a sedative. With 
dexmedetomidine, there are a number of reasons for the growing and renewed 
interest in the use of α2-adrenoceptors agonists as sedatives. 
         Dexmedetomidine compared to Clonidine is a much more selective α2- 
adrenoceptor agonist, which might permit its application in relatively high doses for 
sedation and analgesia without the unwanted vascular effects from activation of α1-
receptors. In addition, Dexmedetomidine is a short acting drug than clonidine and 
has a reversal drug for its sedative effect, Atipamezole. 
These properties render Dexmedetomidine suitable for sedation and analgesia 
during the whole perioperative period: as premedication, as an anesthetic adjunct 
for general and regional anesthesia and as postoperative sedative and analgesic.
33 
Physiology of α2-adrenoceptors 
α2 - receptors are found in many sites throughout the body. α2 -adrenoceptors are 
found in peripheral and central nervous systems, in effector organs such as the 
liver, kidney, pancreas, eye vascular smooth muscles and platelets. Physiologic 
responses mediated by α2 – adrenoceptors vary with location and can account for 
the diversity of their effects.  
 
The different physiologic functions of α2 adrenoreceptors. The top panel depicts the three 
α2 receptor subtypes acting as presynaptic inhibitory feedback receptors to control the 
release of norepinephrine and epinephrine from peripheral or central adult neurons. Also, 
a negative feedback loop has been seen in the adrenal gland. Alpha2B receptors have 
been involved in the development of the placental vascular system during prenatal 
development. The lower panel lists a series of physiologic effects with its associated α2 
adrenoreceptors.(From Paris A, Tonner PH: Dexmedetomidine in anaesthesia. Curr Opin 
Anaesthesiol 18:412-418, 2005) 
 
The classification of α2 - receptors based on anatomical location is complicated 
since these receptors are found in presynaptic, postsynaptic and extrasynaptic 
locations. α2 - adrenoceptors are divided into three subtypes; each subtype is 
responsible uniquely for some of the actions of α2 - receptors.  
             α2A - predominant subtype in CNS, is responsible for the sedative, 
analgesic and sympatholytic effect.  
            α2B - found mainly in the peripheral vasculature, is responsible for the 
short-term hypertensive response. 
            α2C - found in the CNS, is responsible for the anxiolytic effect34. 
All the subtypes produce cellular action by signaling through a Gprotein which 
couples to effector mechanisms. This coupling appears to differ depending on the 
receptor subtype and location. The α2A-adrenoceptor subtype seems to couple in 
an inhibitory fashion to the calcium channel in the Locus Ceruleus of the brainstem, 
whereas, in the vasculature, the α2Badrenoceptor sub type couple in an excitatory 
manner to the same effector mechanism. 
Mechanism of action of Dexmedetomidine 
The mechanism of action of dexmedetomidine is unique and differs from the 
currently used sedative drugs. α2 - adrenoceptors are found in many sites through 
the CNS, however, the highest densities of α2-receptors are found in the Locus 
Ceruleus, the predominant noradrenergic nuclei of the brainstem and an important 
modulator of vigilance. Presynaptic activation of the α2A adrenoceptor in the 
Locus Ceruleus inhibits the release of norepinephrine (NE) and results in the 
sedative and hypnotic effects. In addition, the Locus Ceruleus is the site of origin 
for the descending medullospinal noradrenergic pathway, known to be an important 
modulator of nociceptive neurotransmission. Stimulation of the α2-adrenoceptors in 
this area terminates the propagation of pain signals leading to analgesia. 
Postsynaptic activation of α2-adrenoceptors in the CNS results in a decrease in the 
sympathetic activity leading to hypotension and bradycardia. Also, activation of the 
α2-adrenoceptors in the CNS results in an augmentation of cardiac vagal activity. 
Combined, these effects can produce analgesia, sedation and anxiolysis. 
         At the spinal cord, stimulation of α2-receptors at the substantia gelatinosa of 
the dorsal horn leads to inhibition of the firing of nociceptive neurons and 
inhibition of the release of substance P. Also, the α2- adrenoceptors located at the 
nerve endings have a possible role in the analgesic mechanisms of α2-agonists by 
preventing NE release. The spinal mechanism is the principal mechanism for the 
analgesic action of Dexmedetomidine, even though there is a clear evidence for 
both a supraspinal and peripheral sites of action
35
. 
            α2 - receptors are located on the blood vessels where they mediate 
vasoconstriction and on sympathetic terminals, where they inhibit NE release. The 
responses of activation of α2-adrenoceptors in other areas include contraction of 
vascular and other smooth muscles; decreased salivation, decreased secretion, and 
decreased bowel motility in the gastrointestinal tract, inhibition of renin release, 
increased glomerular filtration, and increased secretion of sodium and water in the 
kidney; decreased insulin release from the pancreas, decreased intraocular pressure, 
decreased platelet aggregation and decreased shivering threshold by 2°C
33
. 
Pharmacodynamics of Dexmedetomidine 
α - adrenoceptors agonists have different α2/α1 selectivity. Clonidine, the first 
developed and the most known α2-agonist is considered as a partial α2-agonist 
since its α2/α1 selectivity is 200:1 while the α2/α1 selectivity of dexmedetomidine 
is 1620:1 and hence it is 8 times more powerful α2-adrenoceptor agonist than 
clonidine and is considered as a full α2 adrenoceptor agonist. The α2-adrenoceptor 
selectivity of dexmedetomidine is dose-dependent; at low to medium doses or at 
slow rates of infusion, high levels of α2 - adrenoceptor selectivity are observed, 
while high doses or rapid infusions of low doses are associated with both α1 and α2 
activities.
36 
CNS effects 
Dexmedetomidine induced sedation qualitatively resembles normal sleep. The 
participation of non rapid eye movement sleep pathways seems to explain why 
patients who appear to be “deeply asleep” from dexmedetomidine are relatively 
easily aroused in much the same way as occurs with natural sleep
37
. This type of 
sedation is branded “cooperative” or “arousable”, to distinguish it from the sedation 
induced by drugs acting on the GABA system such as midazolam or propofol, 
which produce a clouding of consciousness. Sedation induced by dexmedetomidine 
is dose-dependent; however, even low doses might be sufficient to produce 
sedation. 
          However, clinical studies showed that systemic administration of the α2 -
adrenoceptor agonists, dexmedetomidine and clonidine produce sedative and 
opioid-sparing effects in the perioperative setting, providing indirect evidence for 
some analgesic efficacy
38,39,40
, although it is difficult in this special setting to 
distinguish between sedation and analgesia as a cause for this opioid-sparing effect. 
While the analgesic effect of systemic dexmedetomidine is still debatable, 
administration of an α2-agonist (clonidine) via the intrathecal or epidural route 
provides analgesic effects in postoperative pain and in neuropathic pain state 
without severe sedation. This effect is due to sparing of the supraspinal CNS sites 
from excessive drug exposure resulting in robust analgesia without heavy sedation. 
 
  
     The stimulation of the locus caeruleus (LC) by dexmedetomidine (right diagram) 
releases the inhibition the LC has over the ventrolateral preoptic nucleus (VLPO). The 
VLPO subsequently releases γ-aminobutyric acid (GABA) onto the tuberomammillary 
nucleus (TMN). This inhibits the release of the arousal-promoting histamine on the cortex 
and forebrain, inducing the loss of consciousness. (from Ebert T, Maze M: 
Dexmedetomidine: Another arrow for the clinican’s quiver. Anesthesiology 101:569-570, 
2004)       
     
Respiratory effects 
α2 - adrenoceptors do not have an active role in the respiratory center. Therefore, 
dexmedetomidine throughout a broad range of plasma concentration has minimal 
effects on the respiratory system. Coadministration of dexmedetomidine with other 
sedatives, hypnotics or opioids is likely to cause additive effects. 
Cardiovascular effects 
Dexmedetomidine does not appear to have direct effects on the heart. 
In the coronary circulation, dexmedetomidine causes a dose dependent increase in 
coronary vascular resistance and oxygen extraction, but the supply/demand ratio is 
unaltered. A biphasic cardiovascular response has been described after the 
administration of dexmedetomidine. A bolus of 1 μg/kg results in a transient 
increase in blood pressure (BP) and a reflex decrease in heart rate (HR), especially 
in the young healthy patients. This initial response is attributed to the direct effects 
of α2B-adrenoceptor stimulation of vascular smooth muscle. This response can be 
attenuated by a slow infusion over 10 min, but even at slower infusion rates, the 
transient increase in mean BP and the decrease in HR over the first 10 min is 
shown. 
           This initial response lasts for 5 to 10 min and is followed by a decrease in 
BP of  10-20% below baseline and by stabilization of the HR below baseline 
values. Both these effects are presumably caused by an inhibition of central 
sympathetic outflow that overrides the direct effects of dexmedetomidine on the 
vasculature. Hypotension and bradycardia induced by dexmedetomidine are 
reversed by ephedrine and atropine respectively, but large doses are required26. 
Dexmedetomidine decreases the heart rate in dose-depemdent mannerin children. 
This effect is attributed to a centrally mediated sympathetic withdrawal, which 
results in unregulated cholinergic activity. 
 
 
Pharmacokinetics of Dexmedetomidine 
Dexmedetomidine, an imidazole compound, is the active d-isomer of 
medetomidine. Following intravenous administration, dexmedetomidine exhibits 
the following pharmacokinetic parameters: a rapid distribution phase with a 
distribution half-life (t½ α) of 6 min, a terminal elimination half-life (t ½β) of 2 
hours and a steady-state volume of distribution (Vss) of 118 liters and a clearance 
about 39L. Dexmedetomidine exhibits linear kinetics when infused in the dose 
range of 0.2-0.7 μg/kg/h for no more than 24 hours. Dexmedetomidine undergoes 
almost complete biotransformation through direct glucuronidation and cytochrome 
P450 metabolism. Metabolites of biotransformation are excreted in the urine (95%) 
and feces. It is unknown if they had intrinsic activity. 
           The average protein binding of dexmedetomidine is 94%, with negligible 
protein binding displacement by fentanyl, digoxin, theophilline,lidocaine and 
ketorolac. There have been no sex or age-based differences in the pharmacokinetics 
of dexmedetomidine. The dose of dexmedetomidine should be decreased in patients 
with hepatic or renal impairment. Dexmedetomidine does cross the placenta and 
should be only used during pregnancy if the potential benefits justify the potential 
risk to fetus. Dexmedetomidine is a white powder that is freely soluble in water and 
has a pka of 7.1. It is supplied as 100 μg/ml 2 ml vial which must be diluted with 
48 ml of 0.9% sodium chloride prior to administration. For adult patient, 
dexmedetomidine is administered by a loading infusion of 0.5-1 μg/kg over 10 
minutes, followed by a maintenance infusion of 0.2 to 0.7 μg/kg/h. The effect 
appears in 5-10 min, and is reduced in 30-60 min. The maintenance infusion is 
adjusted to achieve the desired level of sedation. 
            The most frequently observed adverse events in patients receiving 
dexmedetomidine for ICU sedation include hypotension, hypertension, nausea, 
bradycardia and atrial fibrillation. Most of these events occur during or after the 
loading dose, therefore, reducing or omitting the loading dose could result in 
decreasing the incidence and severity of these adverse events. 
          Appropriate patient selection for dexmedetomidine administration is crucial; 
because it decreases sympathetic nervous activity, its effects may be most 
pronounced in patients with decreased autonomic nervous system control such as 
the elderly, diabetic patients, patients with chronic hypertension or severe cardiac 
disease such as valve stenosis or regurgitation, advanced heart block, severe 
coronary artery disease or in patients who are already hypotensive and/or 
hypovolemic. 
             Dexmedetomidine does not affect the synthesis, storage or metabolism of  
neurotransmitters and do not block the receptors, thus providing the possibility of 
reversing the hemodynamic effects with vasoactive drugs or the specific alpha2-
antagonist, Atipamezole which acts by increasing the central turnover of 
norepinephrine. Its duration of action is 2 hours 
41
. 
 
 
 
 
 Perioperative uses of dexmedetomidine 
I – Premedication 
Dexmedetomidine possesses anxiolytic, sedative, analgesic, antisialogogue and 
sympatholytic properties, which render it suitable as a premedication agent. 
Dexmedetomidine potentiates the anesthetic effects of all intraoperative anesthetics 
(intravenous, volatile or regional block). Bohrer
42
 showed that preoperative 
administration of intravenous or intramuscular dexmedetomidine resulted in a 
decrease in the induction dose of thiopentone by up to 30%. The administration of 
intramuscular dexmedetomidine at a dose of 1 μg/kg for premedication in 
outpatient cataract surgery resulted in sedation, and decrease in intraocular pressure 
without significant hypotension or bradycardia
43,44
. Also the administration of 
dexmedetomidine for premedication decreases oxygen consumption 
intraoperatively by 8% and postoperatively by 17%. Indications for the use of 
dexmedetomidine as premedication include patients susceptible to preoperative and 
perioperative stress, drug addicts and alcoholics, chronic opioid users and 
hypertensive patients. 
II – Intraoperative uses of dexmedetomidine 
Intraoperative uses of dexmedetomidine include its use as an adjunct to general 
anesthesia, as an adjunct to regional anesthesia, in monitored anesthesia care 
(MAC) or as a sole agent for total intravenous anesthesia (TIVA).  
1– Use of dexmedetomidine as adjunct to general anesthesia 
The use intraoperative dexmedetomidine may increase hemodynamic stability 
because of attenuation of the stress-induced sympathoadrenal responses to 
intubation, during surgery and during emergence from anesthesia. Talke
45
 
evaluated the effects of varying plasma concentrations of dexmedetomidine on HR, 
BP and catecholamines concentrations during emergence from anesthesia in the 
setting of vascular surgery. This study demonstrated that dexmedetomidine 
attenuates the increases in heart rate and plasma norepinephrine levels observed 
during the emergence from anesthesia. 
Administration of intravenous dexmedetomidine produces an anesthetic-sparing 
effect. Aho
46
 showed 25% reduction of maintenance concentrations of isoflurane in 
patients undergoing hysterectomy. Khan found 35%-50% reduction in isoflurane 
concentrations with either low or high doses of dexmedetomidine. Fragen
46
 noted 
17% reduction in sevoflurane requirements for maintenance of anesthesia in elderly 
patients. In addition, the use of dexmedetomidine produces intraoperative and 
postoperative opioid-sparing effect. Aho administered dexmedetomidine at dose of 
0.4 μg/kg in patients undergoing laparoscopic tubal ligation and found a 33% 
decrease in morphine use postoperatively. 
Talke investigated the muscle relaxant effects of dexmedetomidine on the 
neuromuscular junction and found no clinically relevant effects. Dexmedetomidine 
reduces the vasoconstriction threshold and the shivering 
threshold and is associated with a lower incidence of shivering.  
2 – Use of dexmedetomidine for regional anesthesia 
The use of dexmedetomidine as adjuvant in regional anesthesia is still not 
validated. Maarouf
48
 explored the effect of epidural dexmedetomidine on the 
incidence of postoperative shivering in patients undergoing orthopedic surgery. He 
found that patients who received dexmedetomidine at a dose of 100 μg added to 20 
ml 0.5% bupivacaine showed lower incidence in postoperative shivering when 
compared to patients who received epidural bupivacaine alone (10% vs.36%). 
Memis
49
 noted that the addition of 0.5 μg/kg dexmedetomidine to lidocaine for 
intravenous regional anesthesia improves the quality of anesthesia and 
perioperative analgesia without causing side effects. Kanazi et al 
50 
investigated the 
effect of adding a small dose of 3 μg of intrathecal dexmedetomidine to 12 mg 
bupivacaine. They found a significant prolongation of sensory and motor block as 
compared to bupivacaine alone. In this study, the effect of 3 μg intrathecal 
dexmedetomidine was similar to that produced by the addition of 30 μg of 
intrathecal clonidine. 
3 – Use of dexmedetomidine in monitored anesthesia care 
Dexmedetomidine confers arousable sedation with ease of orientation, anxiolysis, 
mild analgesia, lack of respiratory depression and hemodynamic 
stability at moderate doses. These properties allow dexmedetomidine to be an 
almost ideal agent for MAC despite its lack of amnesia and poor controllability 
because of its slow onset and offset. The efficacy, side effects, and recovery 
characteristics of dexmedetomidine were compared to propofol when used for 
MAC. This study showed that dexmedetomidine achieved similar levels of sedation 
to propofol, albeit with a slower onset and offset of sedation. Neither 
dexmedetomidine nor propofol influenced respiratory rate, but propofol resulted in 
lower mean arterial pressure during the intraoperative period. In the recovery room, 
dexmedetomidine was associated with an analgesiasparing effect, slightly increased 
sedation, but no compromise of respiratory function or psychomotor responses. 
Dexmedetomidine in MAC was used successfully in many situations: when patient 
arousability needed to be preserved, as for awake craniotomy, for awake carotid 
endarterectomy and for vitreoretinal surgey. In addition, dexmedetomidine was 
used for sedation in difficult airway patients; during fiberoptic intubation, and for 
sedation of a patient with difficult airway undergoing lumbar laminectomy surgery 
in the prone chest position under spinal anesthesia. 
4 – Use of dexmedetomidine as a sole anesthetic agent 
Ramsay
51
 has used dexmedetomidine as a sole anesthetic agent. The report 
describes three patients who presented for surgery with potential airway 
management challenges. Dexmedetomidine was infused in increasing doses (up to 
10 μg/kg/h) until general anesthesia was attained. No respiratory depression was 
noted, only one patient required chin lift. Also no hypotension or severe 
bradycardia were noted. The rationale for this use of dexmedetomidine is based on 
its known properties to provide sedation, analgesia while avoiding respiratory 
depression at low doses. These effects were maintained at higher doses without 
hemodynamic instability. 
III – Use of dexmedetomidine in the postoperative period 
Dexmedetomidine special properties favour its use in recovery room. In addition to 
its sympatholytic effects, analgesic effects and decreased rate of shivering, the 
preservation of respiratory function allows the continuation of  the 
dexmedetomidine infusion in the extubated, spontaneously breathing patient. The 
possibility of ongoing sedation and sympathetic block could be beneficial in 
reducing high rates of early postoperative ischemic events in high-risk patients 
undergoing non-cardiac surgery. During emergence from anesthesia, 
dexmedetomidine reduces NE levels significantly. However, patients who received 
intraoperative dexmedetomidine needed more fluids to avoid hypotension, a side 
effect that may be unfavorable in volume-sensitive patients with reduced left 
ventricular function. In addition, care should be taken in patients who depend on a 
high level of sympathetic tone or in patients with reduced myocardial function who 
cannot tolerate the decrease in sympathetic tone. Perioperative administration of 
dexmedetomidine could be beneficial in chronic opioid users and alcoholics, in 
high-risk patients as well as in cardiac patients with good to moderately decreased 
left ventricular function. 
IV – Use of Dexmedetomidine in the pediatric-age group 
Only few case reports about the use of dexmedetomidine in the pediatric age group 
are found in the literature 
52,53
. Tobias 
52
 used dexmedetomidine for ICU sedation in 
a10-week old infant requiring mechanical ventilation and in a 14-y old patient after 
posterior spinal fusion for scoliosis. The use of dexmedetomidine at a dose of 0.25 
μg/kg/hr for 24 h in these two cases resulted in acceptable sedation without 
significant hemodynamic changes. Dexmedetomidine was also used for sedation 
and anesthesia in an 11-y old patient undergoing gastroscopy; however, it resulted 
in insufficient sedation. Another study conducted in pediatric-age group explored 
the use of intraoperative dexmedetomidine at different doses with the goal of 
reducing the post sevoflurane agitation in children aged 1-10 y. 
       The optimal dose of dexmedetomidine was 0.3 μg/kg and its use did not result 
in adverse effects
54 
. When compared with propofol for sedation during MRI, 
dexmedetomidine provides adequate sedation during the scan but has a slower 
recovery profile40.One of the major advantages of dexmedetomidine over other 
sedatives is its respiratory effects, which are minimal in adults and children. it does 
not lead to extreme hypoxia or hypercapnia. Indeed, respiratory rate, CO2 tension, 
and oxygen saturation are generally maintained during dexmedetomidine  sedation 
in children. 
 
 
 
 
 
 
 
 
 
 
 
                  
 
 
 
 
 
 
             
 
 
 
            PHARMACOLOGY OF ROPIVACAINE 
 
GENERIC NAME Ropivacaine Hydrochloride injection 
CHEMICAL STRUCTURE
11,55 
 
                   
It is a member of the amino amide class, of local anesthetics. 
It is chemically described as S-(-)-1-propyl-2`,6`pipecoloxylidide 
hydrochloride monohydrate. Ropivacaine belongs to pipecoloxylidide group 
of local anaesthetics with a propyl group attached to the piperidine nitrogen. 
However, it differs from other drugs in the group in that they are racemic 
preparations, while ropivacaine is the first drug to be available as a pure S-(-) 
enantiomer. The drug has the following structural formula: 
PHYSICOCHEMICAL PROPERTIES 
The drug substance is a white crystalline powder, with a chemical formula of 
C17H2N2O.HCl.H2O. The pKa of ropivacaine is approximately the same as 
bupivacaine (8.1) and is similar to that of mepivacaine (7.7). However, 
ropivacaine has an intermediate degree of lipid solubility compared to 
bupivacaine and mepivacaine determined by the N heptane/buffer partition 
coefficient. 
Molecular weight (base) 274 
PKa 8.1 
Potency 4 
Protein binding in % 94 
Fraction % non ionized at pH7.4 17 
Partition Coefficient (N 
heptane/buffer) 
2.9 
 
MECHANISM OF ACTION 
Ropivacaine is a member of the amino amide class of local anesthetics and is 
supplied as the pure S-(-) enantiomer. Local anesthetics block the conduction 
of nerve impulses by blocking the sodium ion channels, thereby decreasing 
sodium ion conductance and preventing depolarization of the cell membrane. 
PHARMACOKINETICS
55 
 Parameters Value 
Elimination (t1/2 in min) 108 
Clearance (L/min) 0.44 
Vdss (L) 59 
Protein Binding (%) 94 
ABSORPTION 
The systemic absorption of ropivacaine after caudal injection is slow 
with peak plasma concentration being achieved much later than bupivacaine. 
This may be due to the intrinsic vasoconstrictor property of ropivacaine at 
low concentrations. 
BIODEGRADATION AND METABOLISM
55 
Ropivacaine is metabolized in liver into 2,6-pipecoloxylidide and 
3-hydroxyropivacaine by cytochrome P-450 enzymes. Both metabolites have 
significantly less local anaesthetic potency than ropivacaine. About 1% is 
excreted unchanged in the urine. Its Clearance is higher than bupivacaine and 
elimination half-time shorter
11
. The higher clearance may offer an advantage 
over bupivacaine in terms of systemic toxicity. It has a lipid solubility 
intermediate between lignocaine and bupivacaine and is highly bound to 
alpha1-acid glycoprotein.  
 
SYSTEMIC TOXICITY 
Central Nervous System Toxicity 
Ropivacaine produces similar spectrum of symptoms involving the central 
nervous system like bupivacaine but the duration of symptoms is shorter with 
the former. Moreover, studies have shown that higher doses and free plasma 
concentrations of ropivacaine were tolerated before symptoms were 
elicited
56
. 
 Cardiovascular System Toxicity: 
Cardiovascular effects are less pronounced with ropivacaine. The very 
slow reversal of Na+channel blockade after a cardiac action potential, which 
is a hallmark of bupivacaine, is considerably faster with ropivacaine. In 
addition, the negative inotropic potency of ropivacaine on isolated cardiac 
tissue appears to be considerably less than that of bupivacaine
57,58
. Studies in 
animals show that aggressive cardiac resuscitation after an intentional 
intravenous bolus in dogs leads to effective reversal of the toxic effects far 
more frequently with ropivacaine than with bupivacaine indicating that 
ropivacaine is less cardiotoxic
59
.  
The greater safety of ropivacaine than bupivacaine may be related both 
to the reduced toxicity of the single (S) - isomer and the difference between 
the propyl and butyl –N- piperidine substituent60.  
 
 
 
 
 
 
 
PHARMACOLOGY OF BUPIVACAINE 
HISTORY 
It is an amide linked local anesthetic synthesized by B.A.F. 
Ekenstam in 1957 and introduced into clinical practice by Talivuo in 1963. 
CHEMICAL STRUCTURE
55 
                   
An amino amide local anesthetic having a benzene ring (lipophilic) at one 
end linked by an amide group to a tertiary amine (hydrophilic) on the other 
end of the molecule. It belongs to the group of pipecoloxylidide local 
anaethetics. All drugs in this group like mepivacaine, ropivacaine, 
levobupivacaine possess chirality due to the asymmetric carbon atom so that 
they may have optical isomers (enantiomers). The enantiomers may vary in 
their pharmacokinetics, pharmacodynamics and toxicity. Hence, 
administering a racemic drug mixture is, in reality, administration of two 
different drugs
61
. Bupivacaine is available as a racemic mixture with the S-
enantiomer less toxic than the R form. 
  
  
PHYSICOCHEMICAL PROPERTIES 
Molecular weight                                                                          288 
pKa                                                                                                8.1 
Partition coefficient(N heptane/ buffer)                                        10 
Potency                                                                                            4 
Protein binding in %                                                                      95 
Fraction % non ionized at pH 7.4                                                  17 
Lipid solubility                                                                               28 
 
MECHANISM OF ACTION 
Local anaesthetics prevent transmission of nerve impulses (conduction 
blockade) by inhibiting passage of sodium ions through ionselective sodium 
channels in nerve membranes
62
. They diffuse in their uncharged base form 
through neural sheaths and the axonal membrane to the internal surface of 
cell membrane sodium ion channels. Here, they combine with hydrogen ions 
to form a cationic species which enters the internal opening of the sodium ion 
channel and binds with the channel in the inactivated-closed state. This 
produces blockade of the sodium ion channel thereby decreasing sodium ion 
permeability and preventing depolarization of the cell membrane. 
                Binding affinities of local anaesthetics to the sodium ion channels 
are stereospecific thereby contributing to their differing potencies among the 
enantiomers. In addition to sodium ion channels, local anaesthetics block 
voltage-dependent potassium channels but with lower affinity. Other 
additional actions may include blockade of voltage dependent calcium ion 
channels (L-type most sensitive) and their action on G-protein coupled 
receptors. 
            Differential conduction blockade is illustrated by selective blockade 
of small C fibers and small- and medium-sized A fibers, with loss of pain and 
temperature and preservation of touch, proprioception and motor function at 
low concentrations of local anaesthetics. 
PHARMACOKINETICS 
The onset and duration of conduction blockade is related to the pKa, 
lipid solubility and extent of protein binding of the drug. A low pKa and high 
lipid solubility are associated with a long duration of action. 
ABSORPTION 
The absorption of bupivacaine from its site of  injection into the 
systemic circulation is influenced by the site of injection and dosage and use 
of epinephrine but the ultimate plasma concentration is determined by the 
rate of tissue distribution and the rate of clearance of the drug.Lipid solubility 
is important in the tissue redistribution as well as being a primary 
determinant of the drug potency with bupivacaine being highly lipid soluble 
and more potent. Protein binding will also influence its distribution and 
excretion that parallels the lipid solubility and is inversely related to its 
plasma concentration 
 Pharmacokinetics 
Elimination half life                                                              210 min 
Volume of distribution (Vdss)                                                 73 L 
Clearance (l/min)                                                                      0.47 
Toxic plasma concentration                                                >3 mics/ml 
 
BIODEGRADATION AND ELIMINATION 
Liver is the site of metabolism. Two major factors controlling the clearance 
of the amide linked local anesthetics are hepatic blood flow and hepatic 
function. The principal pathways are N dealkylation, aromatic hydroxylation, 
amide hydrolysis and conjugation (ref). The mean total urinary excretion of 
bupivacaine and its dealkylation and hydroxylation metabolites account for 
>40% of the total anaesthetic dose. Alpha1 acid glycoprotein is the most 
important plasma protein binding site of bupivacaine. 
 
 
 
 
ADVERSE EFFECTS AND COMPLICATIONS 
Systemic toxicity 
This is due to an excess plasma concentration of the drug. Plasma 
concentrations are determined by the rate of drug entrance into the systemic 
circulation relative to their redistribution to inactive tissue sites and clearance 
by metabolism. The magnitude of the toxicity depends on dose administered, 
vascularity of the injection site, presence of epinephrine in the solution and 
the protein binding of bupivacaine. 
Central Nervous System 
Circumoral numbness is often an early symptom with restlessness, 
vertigo,tinnitus, and difficulty in focusing developing later. Further increases 
in the CNS concentration result in slurred speech and skeletal muscle 
twitching which signals the imminence of tonic-clonic seizures. Seizures are 
usually followed by CNS depression, which may be accompanied by 
hypotension and apnea. The typical plasma concentration of bupivacaine 
associated with seizures is 4.5-5.5mic/ml. Hypoxia, Hypocarbia, 
hyperkalemia and acidosis can decrease the seizure threshold and increase 
CNS toxicity. The treatment includes oxygenation, ventilation and 
benzodiazepine or barbiturates for termination of the seizures. 
Cardiovascular system 
The cardiovascular system is more resistant to the toxic effects of high 
plasma concentrations than is the CNS. Part of the cardiac toxicity that results 
from high plasma concentrations occurs because it also blocks the sodium 
channels in the heart and this block of the inactivated state of the cardiac 
sodium and potassium (hKv1.5) channels is stereospecific with R 
bupivacaine, being more potent than S-bupivacaine
9 
. The primary cardiac 
electrophysiologic effect of local anaesthetics is a decrease in the rate of 
depolarization in the fast conducting tissues of Purkinje fibers and ventricular 
muscle
63
. Action potential and the effective refractory period are also 
decreased by local anesthetics. 
        Accidental intravenous injection of bupivacaine may result in 
precipitous hypotension, cardiac dysrhythmias like Premature ventricular 
contractions, Supraventricular tachycardia, Atrioventricular heart block and 
Ventricular tachycardia that may be resistant to conventional resuscitative 
measures. Cardiotoxic plasma concentrations are 8-10 mic/ml. Moreover, 
bupivacaine depress the maximal depolarization rate of the cardiac action 
potential (Vmax) by virtue of its ability to inhibit sodium ion influx via 
sodium channels. This Vmax depression by bupivacaine is considerably more 
than lidocaine and ropivacaine.In addition, the rate of recovery from a use-
dependent block is slower in bupivacaine-treated papillary muscles. 
Moreover, high blood levels of bupivacaine will prolong conduction time 
through various parts of the heart indicated by prolongation of PR interval 
and QRS complex. It also exerts dose-dependent negative inotropic action on 
cardiac muscle. 
                 EMERGENCE DELIRIUM IN CHILDREN 
 
 
Emergence delirium (ED) is not a new phenomenon in clinical practice. 
In the early 1960s, Eckenhoff et al  were the first to report the signs of 
hyperexcitation in patients emerging from ether, cyclopropane, or ketamine 
anesthesia, particularly when administered for tonsillectomy, thyroidectomy, 
and circumcision. Children experienced postanesthesia agitation more often 
than adults (12%–13% vs 5.3%). With the recognition of postoperative pain 
management in children and the increased use of analgesics, the incidence of 
emergence agitation (EA) was attenuated. However, with the introduction 
into clinical practice of the new short-acting, volatile anesthetics sevoflurane 
and desflurane, the problem of ED reemerged. When children were aroused 
from anesthesia in a quiet manner, they suddenly entered, often due to an 
external stimulus, a state of excitation in which they could not be consoled by 
the usual methods. Restless recovery from anesthesia may not only cause 
injury to the child or to the surgical site, but may also lead to the accidental 
removal of surgical dressings, IV catheters, and drains. Extra nursing care 
may often be necessary as well as supplemental sedative and/or analgesic 
medications, which may delay patient discharge from hospital. This adverse 
postanesthesia event raises the question about the “quality” of a particular 
anesthetic. Parents who witness ED in their child may worry about permanent 
sequelae. 
Sikich and Lerman defined ED as “a disturbance in a child’s awareness of 
and attention to his/her environment with disorientation and perceptual 
alterations including hypersensitivity to stimuli and hyperactive motor 
behaviour in the immediate postanesthesia period.” ED usually occurs within 
the first 30 min of recovery from anesthesia, is self-limited (5–15 min), and 
often resolves spontaneously. The incidence of EA/ED largely depends on 
definition, age, anesthetic technique, surgical procedure, and application of 
adjunct medication. Generally, it ranges from 10% to 50%, but may be as 
high as 80% . 
ANESTHESIA-RELATED FACTORS 
Rapid Emergence 
           Postanesthesia agitation has been noted more often with the newer, 
less soluble, inhaled anesthetics, such as desflurane and sevoflurane, than 
with other volatile ones. It has been postulated that rapid awakening after the 
use of the insoluble anesthetics may initiate EA/ED by worsening a child’s 
underlying sense of apprehension when finding himself in an unfamiliar 
environment. Some parents claim the patient’s behaviour upon emergence 
was the same as when he was suddenly awakened from deep sleep. Older 
children and adults usually become oriented rapidly, whereas preschool-aged 
children, who are less able to cope with environmental stresses, tend to 
become agitated and delirious. However, recovery from propofol anesthesia 
is also rapid, smooth and pleasant. Several studies have shown that 
sevoflurane anesthesia is associated with a higher incidence of EA/ED 
compared with propofol. Delaying emergence by a slow, stepwise decrease in 
the concentration of inspired sevoflurane at the end of surgery did not reduce 
the incidence of EA. 
Intrinsic Characteristics of an Anesthetic 
Most authors have documented that EA/ED occurs more often after 
sevoflurane than after halothane anesthesia. Some authors have speculated 
that two unique, intrinsic characteristics of sevoflurane might account for the 
development of EA/ED. First, this anesthetic exerts an irritating side effect on 
the central nervous system (CNS). Second, although sevoflurane degradation 
products appear to cause no organ damage themselves, data are lacking on 
their possible interactions with other types of medications. As for the 
eventual neurotoxic influence of sevoflurane degradation products, there is 
no supporting scientific evidence. 
SURGERY-RELATED FACTORS 
Pain 
Postoperative pain has been the most confounding variable when assessing a 
child’s behavior upon emergence because of the overlapping clinical picture 
with EA/ED. Inadequate pain relief may be the cause of agitation, 
particularly after short surgical procedures for which peak effects of 
analgesics may be delayed until the child is completely awake. In several 
studies, the preemptive analgesic approach successfully reduced EA/ED, 
suggesting that pain may be its major source. Bock et al studied the effect of 
clonidine on EA in 80 children aged 3–8 yr undergoing minor day-case 
surgery who were anesthetized with sevoflurane. The children received a 
caudal block for perioperative pain relief. A dose of 3µ/kg clonidine was 
found to prevent agitation whether administered IV or caudally. Other 
authors demonstrated that an IV dose of 2µ/kg clonidine was efficient under 
similar conditions. Another more selective α2 receptor agonist, 
dexmedetomidine, also reduced sevoflurane-induced EA/ED when given 
prophylactically. On the other hand, post anesthesia agitation has been 
observed when pain was efficiently treated or even when absent. Weldon et al 
studied premedicated children aged 12 months to 6 years undergoing inguinal 
hernia repair, whose postoperative pain was managed with a preemptive 
caudal block. At 5 min after arrival in the PACU, agitation was significantly 
more frequent in sevoflurane anesthetized children compared with halothane 
anesthetized children (26% vs 6%). A higher incidence of EA was also 
recorded in patients who received sevoflurane for non painful interventions, 
such as magnetic resonance imaging scanning and eye examinations. In 
contrast, children anesthetized with halothane and propofol for the same 
procedures, respectively, were free of agitation. These findings clearly 
suggest that EA/ED may be a clinical phenomenon that is separate from pain. 
 
 
Surgery Type 
Surgical procedures that involve the tonsils, thyroid, middle ear, and eye have 
been reported to have higher incidences of postoperative agitation and 
restlessness. Eckenhoff et al  speculated that a “sense of suffocation”during 
emergence from anesthesia may contribute to EA in patients undergoing head 
and neck surgery. However, there are no supporting scientific data to date. 
PATIENT-RELATED FACTORS 
Age 
Aono et al  found that ED appeared more often with sevoflurane than 
with halothane in preschool boys aged 3–5 yr (40% vs 10%). The difference 
was not observed in the school-aged population. All children received oral 
diazepam for premedication and a caudal block for peri operative pain 
control. 
The authors speculated that the psychological immaturity of preschool 
children, coupled with the rapid awakening in a strange environment, may 
have been the main cause of ED. Generally, younger children are more likely 
to show altered behaviour upon recovery from anesthesia. The subpopulation 
of those aged 2–5 yr seems to be the most vulnerable as they are easily 
confused and frightened by unexpected and unpredictable experiences. In a 
recent commentary on the diagnosis of delirium in pediatric patients, Martini 
addressed the role of brain maturation in the genesis of this phenomenon. He 
pointed out that the pediatric brain is almost a mirror image of a normal 
agerelated regressive process with a consequent decline in norepinephrine, 
acetylcholine, dopamine and γ amino butyric acid (GABA). Thus, the 
development of cholinergic function and the hippocampus may suggest clues 
about the relative susceptibility of younger children to delirium. 
Preoperative Anxiety 
Intense preoperative anxiety, both in children and their parents has been 
associated with an increased likelihood of restless recovery from anesthesia. 
Temperament 
Children who are more emotional, more impulsive, less social and less 
adaptable to environmental changes were identified to be at risk for 
developing postanesthesia agitation. It is likely that there is some substrate 
innate to each child that will elicit, to a larger or lesser extent, a fearful 
response to outside stimuli, depending on the interaction between the child 
and the environment. This reactivity, which describes the “excitability, 
responsivity or arousability” of the child, might be the underlying substrate 
from which both preoperative anxiety and ED arise. Patient-related factors 
are an important source of variability among studies in the incidence of 
EA/ED as they are most difficult to control when investigating this 
phenomenon. 
 
 
 
ADJUNCT MEDICATION 
Numerous drugs, including anticholinergics, droperidol, barbiturates, 
opioids, benzodiazepines, and metoclopramide, may contribute to 
behavioural disturbances after anaesthesia. 
        In summary, none of the above-discussed factors had been proven to 
be the sole underlying cause of EA/ED. However, each factor, especially 
when combined with the others, may influence the behaviour of a child 
emerging from anaesthesia.  
PREVENTION AND TREATMENT 
Given that the EA/ED etiology is still unknown, a clear-cut strategy for 
its prevention has not been developed. Data on the possible role of 
premedication in reducing EA/ED have been conflicting. Sevoflurane at high 
concentrations has been shown to enhance and at low concentrations to block 
the GABA -A receptor-mediated inhibition of neurotransmission in the CNS. 
On the other hand, there are studies in which midazolam premedication did 
not show any benefit on the quality of recovery from anesthesia . This finding 
may possibly be the result of applying a nonspecific measuring tool or a 
provision of inadequate pain control. Benzodiazepines themselves are 
associated with paradoxical reactions and agitation that are reversed with  
flumazenil61. Furthermore, the antianalgesic effects of midazolam might 
worsen pain and increase the incidence of nonspecific agitation that 
resembles ED. 
Various preemptive analgesic approaches, including caudal block, fentanyl, 
ketorolac, clonidine and dexmedetomidine, have been recommended to 
eliminate pain as a potential source of discomfort and agitation. The decision 
of whether to treat EA/ED with additional medication depends upon the 
severity and duration of symptoms. Many studies have shown that EA/ED is 
self-limited, resolving without pharmacological Intervention over time. 
“Rescue” medication includes analgesics, benzodiazepines, and hypnotics. A 
single bolus dose of dexmedetomidine 0.5 µ/kg was also shown to be 
efficient in the PACU for ED. 
PHYSIOLOGY OF PAIN 
Pain is a complex constellation of unpleasant sensory, perceptual and 
emotional experiences and certain associated autonomic, psychological, 
emotional, and behavioral responses. Untreated pain in children, as the result 
of vaccinations and blood draws, surgery,headaches or repeated painful 
procedures, can have long-term effects. 
NEUROPHYSIOLOGY OF PAIN 
A variety of chemical, thermal or mechanical insults can result in the 
sensation of pain. A mosaic of pain receptors or nociceptors in the body 
tissues ultimately project to pain centers in the brain. The somatosensory 
system is subserved by different groups of afferent fibers differentiated by 
their anatomy, rate of transmission and sensory modality transmitted. The 
afferent fibres that relay pain information to the dorsal horn of the spinal cord 
and then on to the brain include smalldiameter C-fibres and thinly myelinated 
A-delta fibres. The dorsal horn is organized into fairly discrete lamellae. The 
primary afferent first-order synapses (nociceptive-specific neurons) are 
located in layers 1, 2 and 5 of the dorsal horn. Signals are then relayed 
rostrally to the thalamus and the cortex. In addition, afferent impulses are 
carried to the brainstem, limbic system, and hypothalamus to mediate many 
of the autonomic and affective component responses to noxious stimuli. 
Deeper in the dorsal horn are located wide dynamic range neurons (WDR) 
that appear to be important in the development of hyperalgesia or wind-up 
phenomenon. These neurons may be responsible for firing in pain syndromes 
that are not associated with obvious tissue-damage as well. 
DEVELOPMENTAL NEUROBIOLOGY OF PAIN 
Nociceptive pathways in the periphery, spinal cord, and brain develop in a 
series of stages through the second and third trimester in humans. By 26 
weeks of postconceptual age there is sufficient maturation of peripheral and 
spinal afferent transmission for the late gestation fetus or preterm neonate to 
respond to tissue injury or inflammation with withdrawal reflexes, autonomic 
arousal and hormonal-metabolic stress responses. There are also changes in 
responsiveness after injury or repetitive stimulation indicative of central 
sensitization. 
It is important to understand that pain due to surgical procedures not only 
results in an immediate nociceptive response but also results in changes in the 
nociceptive activation pathways that lead to hypersensitivity, hyperalgesia 
and allodynia. 
REVIEW OF LITERATURE 
 
A.M.El-Hennawy et al 
12
compared the analgesic effects and sideeffects of 
Dexmedetomidine and clonidine added to bupivacaine in paediatric patients 
undergoing lower abdominal surgeries and concluded that addition of  
dexmedetomidine or clonidine to caudal bupivacaine significantly prolonged the 
duration of analgesia in children undergoing lower abdominal surgeries. 
Mausumi neogi et al
13
 did a comparative study between clonidine and 
dexmedetomidine used as adjuncts to ropivacaine for caudal analgesia in paediatric 
patients and concluded that addition of both clonidine and dexmedetomidine with 
ropivacaine administered caudally significantly increased the duration of analgesia. 
Saadawy et al
14
  studied the effect of dexmedetomidine on the characteristics of 
bupivacaine in caudal block in children and concluded that caudal 
dexmedetomidine provides excellent analgesia over a 24hr period without side 
effects. 
G.Ivani et al
15
  studied ropivacaine with clonidine combination for caudal 
blockade in children and concluded that the combination of clonidine 2mic/kg and 
ropivacaine 0.1% was associated with an improved quality of post operative 
analgesia compared to plain 0.2% ropivacaine without any significant post 
operative sedation. 
Obayah et al
16
 evaluated the efficacy of adding dexmedetomidine to bupivacaine 
on the duration of post operative analgesia in children who underwentt cleft palate 
repair and concluded that addition of dexmedetomidine to bupivacaine for greater 
palatine nerve block prolongs the post operative analgesia after cleft palate repair 
with clinically no relevant side effects. 
Thomas R.Vetter et al
17
  studied a comparison of single dose caudal clonidine, 
morphine or hydromorphone combined with ropivacaine in paediatric patients 
undergoing ureteral reimplantation and concluded that the use of caudal clonidine 
may be superior to caudal opiods after paediatric ureteral reimplantation. 
Giovanni Cucchiaro et al
18
 studied the effects of clonidine on post operative 
analgesia after peripheral nerve blockade in children and concluded that the 
addition of clonidine 1mic/kg to low concentrations of ropivacaine or bupivacaine ( 
0.1% - 0.2% ) can extend the duration of sensory block and analgesia time in 
children. 
Akbas M et al
19
 studied a comparison of the effects of clonidine and ketamine 
added to ropivacaine on stress hormone levels and duration of caudal analgesia and 
concluded that caudal 0.2% ropivacaine 0.75ml/kg with clonidine 1mic/kg for 
subumblical surgery attenuates changes in postoperative cortisol, insulin and blood 
glucose response to surgery 
Sharpe et al
20
 studied a comparison of caudal bupivacaine alone with bupivacaine 
plus two doses of clonidine for circumcision in paediatric population and concluded 
that there was an increase in analgesic duration with increasing doses of clonidine 
administered caudally and the arousal time was also prolonged. 
Bock M et al
21 
 studied a comparison of caudal clonidine and intravenous clonidine 
in the prevention of agitation after sevoflurane in children and found that 
prophylactic use of clonidine decreases the sevoflurane induced agitation at a dose 
of 4mic/kg, independent of the route of administration. 
Constant I. et al
22
 evaluated the addition of clonidine or fentanyl to local 
anaesthetics on the duration of surgical anaesthesia after single shot caudal block in 
children and concluded that the addition of clonidine or fentanyl to local anesthetics 
prolongs the duration of surgical anesthesia. 
Clonidine has some advantages over fenatnyl as it does not produce clinically 
significant side effects. 
P.A.Lonnqvist et al
23
 studied the pharmacokinetics after caudal block of 
ropivacaine ( 2mg/ml, 1mg/kg ) in 20 children undergoing subumblical surgery and 
concluded that ropivacaine was well tolerated and provided satisfactory 
postoperative pain relief without observable motor block. 
Alparslan Turan et al
24
 studied caudal ropivacaine and neostigmine in paediatric 
surgery and found that a single caudal injection of neostigmine when added to 
ropivacaine offers an advantage over ropivacaine alone for postoperative pain relief 
in children undergoing genitourinary surgery. 
 
       M.J. Da Conceicao et al 
25
 (British Journal of Anaesthesia 1998). The authors 
studied 60 children aged 3-6 years who received either 0.375% ropivacaine or 
0.375% bupivacaine 1ml/kg by caudal route after induction of anaesthesia. They 
observed that ropivacaine group showed a shorter duration of motor block than the 
bupivacaine group (P<0.05). They summarized that caudal ropivacaine appears to 
induce similar sensory block with shorter motor block to that of bupivacaine. 
         H. Wulf et al 
26
 .  The authors evaluated the pharmacokinetics of 1ml/kg 
0.2% ropivacaine in 25 infants and toddlers after caudal epidural injection. Mean 
(S.D.) Peak Plasma concentrations of ropivacaine were 0.73(0.27) in infants and 
0.49 (0.21) μg/ml in toddlers and there were no signs of local anaesthetic toxicity. 
They observed that maximum plasma concentrations occurred after a median 
(range) period of 60(15-90) min and 52.5 (30-120) min in infants and toddlers 
respectively. They concluded that from a pharmacokinetic point of view caudal 
blockade with 0.2% ropivacaine 1ml/kg can be regarded as a safe dose in children. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Study design: 
Prospective randomized double blinded study. 
Population: 
60 patients 
Inclusion criteria: 
ASA I and II patients between 1 yr to 6 years of age undergoing 
Infra-imbilical surgeries. 
Sample size: 
                 GROUP  BD : 0.25% Bupivacaine 1ml/kg with          
                                         Dexmedetomidine 1µg/kg  
               GROUP  RD  : 0.2% Ropivacaine 1ml/kg with  
                                          Dexmedetomidine 1µg/kg 
Exclusion criteria : 
• Parent refusal 
•  patients with ASA physical status III-IV,  
• known history of hypersensitivity to any of the drugs used, 
•  infection at the site of block,  
• bleeding diathesis,  
• pre-existing neurological or spinal disease and  
• skeletal deformities 
• history of developmental delay  
Pre operative evaluation: 
In all children, age, I.P. No., body weight, and baseline vital 
parameters were recorded. History regarding previous anaesthesia, surgery, 
any significant medical illness, medications and allergy were recorded. 
Complete physical examination and airway assessment were done. Following 
laboratory investigations were done: haemoglobin %, blood sugar, urea, 
serum creatinine and urine analysis 
Study Method: 
On admission, a thorough preoperative evaluation of the patient was 
done. A written informed consent was taken from the parents after explaining 
the procedure, its advantages and disadvantages. Basal vital parameters like 
heart rate, blood pressure and Oxygen saturation and ECG were recorded. 
Intravenous access was secured with appropriate size intravenous canula.  Inj. 
Atropine 0.01mg/kg IV and Inj. Midazolam 0.03mg/kg IV were given as 
premedication. Maintenance infusion was started with Ringer Lactate(4-2-1 
rule)  and  Children were pre-oxygenated with 100%O2 for 3 minutes and 
induced with inj.Fentanyl 2µg/kg iv, inj.Propofol 2mg/kg iv, inj.Suxa  1.5 
mg/kg iv .Under direct laryngoscopy with the appropriate size laryngoscope 
blade,orotracheal intubation was performed with the appropriate size 
endotracheal tube and the tube position confirmed by capnography and tube 
secured. Maintained  with Oxygen ,Nitrous Oxide (50:50) and sevoflurane.  
      The child was put in the left lateral position and under aseptic precautions 
the sacral hiatus was identified. Caudal epidural space was identified by 
using the loss of resistance technique and swoosh test and  the study drug was 
deposited after confirming negative aspiration for blood and CSF. To detect 
and avoid an inadvertent intravascular or subarachnoid injection, the syringe 
was repeatedly aspirated and the local anaesthetic was injected in increments 
while watching vital signs and the ECG monitor. 
Intra-operatively, the onset of action of the study drug and duration of 
surgery were noted. Heart rate, blood pressure and SPO2 were recorded 
before and after induction and every 5 mins thereafter till the surgery was 
over. Post-operatively, the vital parameters were recorded every 15 mins and 
also the duration of sedation, duration of analgesia, any complications like 
bradycardia, hypotension, dry mouth, retention of urine, respiratory 
depression, nausea, vomiting etc. were noted in each group. The duration of 
analgesia was assessed by using the subjective pain scale in children more 
than 3years of age who can verbally express pain and observational pain 
scale for rest of the children who cannot verbally express pain. If the child 
complained of pain or if the pain score is >/=4, the child received 
Paracetamol suppository 15mg/kg as a rescue analgesic. Sedation was 
assessed using Sedation score. Motor block was assessed by Modified 
Bromage scale. 
 
 
Four Point Sedation Score:    1. Asleep, not arousable by verbal contact.  
                                                     2. Sleep, arousable by verbal contact.  
                                                    3. Drowsy not sleeping.   
                                                    4. Alert/ awake. 
 
Modified Bromage Scale:   Bromage 0- Patient is able to move the hip, knee and  
                                                                ankle.  
                            Bromage 1- Patient is unable to move the hip but able to move  
                                               the knee and  ankle.  
                            Bromage 2 - Patient is unable to move the hip and knee but able  
                                               to move the ankle.  
                            Bromage 3 - Patient is unable to move the hip, knee and ankle  
   
HR        >10% to < 20% ofpreoperative   
20% to 30% of preoperative level 
 >30% of preoperative level 
0  
1  
2  
BP >10% to < 20% of preoperative level  
20 % to 30% of preoperative level  
>30% of preoperative level 
0  
1  
2  
CRYING Not crying  
Crying but responds to tender loving care  
Crying and does not respond to tender loving care 
0  
1  
2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Behaviour during emergence :  
1. calm 
            2. not calm but could be easily calmed 
            3. not easily calmed, moderately   agitated or  restless 
                    4. combative, excited or disoriented   
The following times were recorded: 
1. The anaesthesia time (time from induction of anesthesia to the end of 
surgery when sevoflurane discontinued). 
2. Time from caudal block to skin incision. 
3. Time from caudal block to end of surgery. 
4. Emergence time (time from the end of surgery to opening the eyes on 
calling). 
              Complications such as PONV, respiratory depression, hypotension 
and bradycardia were also noted. Respiratory depression was defined as a 
decrease in SpO2 of <95% requiring supplementary oxygen. Hypotension 
was defined as systolic arterial pressure 70 plus twice the age in years and 
associated with altered peripheral perfusion. Bradycardia was defined as 
heart rate below 80 beats/ min for ages, 1 yr and 60 beats/ min for ages above 
1 yr. Delayed anaesthetic emergence was defined as 20 min elapsing from the 
end of surgery to exiting the operating theatre. Failure of caudal block was 
defined as any increase in HR or MAP >20% than pre incision values.  
 
 STATISTICAL ANALYSIS 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of computer 
by using  SPSS 16 software. 
 Using this software, percentages, means, standard deviations were 
calculated and  'p'  values were calculated from Student ‘t’ test for raw data 
for two variables, and chi square test for consolidated data to test the 
significance of difference between variables.  
A 'p' value less than 0.05 is taken to denote significant 
relationship. 
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
DEMOGRAPHIC VARIABLES 
Age distribution among Groups BD and RD 
Age in months 
BD Group RD Group Total 
No. % No. % No. % 
 12 – 24 12 40.00 7 23.33 19 31.67 
 25 – 36 6 20.00 5 16.67 11 18.33 
 37 – 48 3 10.00 4 13.33 7 11.67 
 49 – 60 2 6.67 5 16.67 7 11.67 
 61 – 72 7 23.33 9 30.00 16 26.67 
Total 30 100.00 30 100.00 60 100.00 
Mean 39.2 47.8     
SD 22.982 21.417     
p' value 0.244  Not Significant     
               
 
The mean age of the BD group was 39.2±22.9 months and the RD group 
was 47.8±21.4 months. The difference between the two groups was not statistically 
significant ( P > 0.05 ). 
 Distribution of sex in between BD and RD groups 
Sex 
BD Group RD Group Total 
No. % No. % No. % 
MALE 25 83.33 29 96.67 54 90.00 
FEMALE 5 16.67 1 3.33 6 10.00 
Total 30 100.00 30 100.00 60 100.00 
p' value 0.197  Not significant   
 
     
 
 
The above table shows sex wise distribution of BD and RD group. In the BD 
group 83.33% were male and the remaining 16.67% were females. But in the 
RD group 96.67% were males and the remaining 3.33% were females. Both 
groups were comparable but no statistical difference exists.  
 
 
 
COMPARISON OF WEIGHT DISTRIBUTION IN BD AND RD GROUPS 
Weight in kgs 
BD Group RD Group Total 
  % No. % No. % 
 6 - 10 15 50.00 9 30.00 24 40.00 
 11 - 15 6 20.00 17 56.67 23 38.33 
 16 - 20  9 30.00 4 13.33 13 21.67 
Total 30 100.00 30 100.00 60 100.00 
Mean 12.317 12.9     
SD 3.984 3.239     
p' value 0.536 Not significant     
 
 
 
        The mean weight of the BD group was 12.317 ± 3.9 kg  and  RD group  was   
12.9±3.2 kg. The difference of weight between the two groups was not statistically 
significant ( P >0.05) 
 
 DURATION OF SURGERY 
Variables 
BD Group RD Group Difference 
Of Mean 
t-value p-value 
Mean S.D Mean S.D 
Duration Of 
Surgery (mins) 
45.333 17.066 41.667 15.388 3.666 0.874 0.874 
 
 
 
  
   The mean duration of surgery of BD Group was  45.3 ±17.06 minutes and 
RD Group was 41.66 ±15.38 minutes. The Difference between the means was 
not statistically significant.( P >0.05) 
 
  Comparison of type of surgery in both Groups 
 
Types Of Surgery BD Group RD Group 
circumscision 6 8 
herniotomy 12 11 
PVSL 6 4 
orchidopexy 4 3 
urethroplasty 2 4 
Total 30 30 
p' value 0.82  Not significant 
PVSL – Processus vaginalis sac ligation 
               
 
 
The type of surgeries between the both groups was also comparable but not 
statistically significant. 
 Onset of action 
BD Group 
(mins) 
RD Group 
(mins) 
P'value   
Mean S.D Mean S.D     
6.707 0.236 6.653 0.157 0.307 Not sig 
 
 
 
 
The mean onset of action in group BD was 6.707±0.23mins and in group 
RD was 6.653±0.157. Statistically Not significant. 
 
Comparison of Haemodynamic variables 
    BD Group RD Group 
Difference 
Of Mean 
t' P'value  
    Mean S.D Mean S.D        
Pre op 
PR 99.4 7.262 97.467 5.501 1.933 1.162 0.250 Not sig 
MAP 75.6 4.344 76.333 4.373 -0.652 -0.733 0.517 Not sig 
SPO2 99.53 0.571 99.5 0.572 0.033 0.226 0.822 Not sig 
Intraop 
PR 88.708 6.357 91.675 6.564 -2.967 -1.778 0.081 Not sig 
MAP 70.283 2.204 71.767 3.657 -1.483 -1.903 0.062 Not sig 
SPO2 99.558 0.224 99.544 0.223 0.0139 0.241 0.811 Not sig 
Post op 
PR 89.487 6.443 92.093 6.363 -2.607 -1.577 0.120 Not sig 
MAP 71.58 2.246 71.967 2.837 -4.567 -0.586 0.560 Not sig 
SPO2 99.133 0.376 99.013 0.53 0.12 1.011 0.316 Not sig 
 
 
The preoperative, intraoperative and post operative haemodyanamic changes 
between the Groups were comparable and were not statistically significant 
and the therapeutic interventions were not required. 
Duration Of Sedation:  
Time in 
Hours 
BD Group RD Group P'value Significance 
Mean S.D Mean S.D    
2 2.967 0.183 2.9 0.305 0.309 Not sig 
4 3 0 2.933 0.254 0.155 Not sig 
6 2 0 1.9 0.305 0.078 Not sig 
8 2.033 0.183 1.933 0.254 0.085 Not sig 
12 1.333 0.479 1.367 0.49 0.791 
Not sig 
 
 
          The Sedation score between the two Groups were comparable and were 
not statistically significant. 
 
 
 
Emergence Time and Emergence Behaviour score 
Variables BD Group RD Group 
Difference 
Of Mean 
t' P'value  
  Mean S.D Mean S.D        
Emergence Time 4.467 0.9 4.6 0.968 -0.133 -0.553 0.583 
Not 
sig 
Emergence 
Behaviour Score 
3.633 0.964 3.267 0.45 0.367 1.887 0.064 
Not 
sig 
 
 
 
 
                  The emergence time and Emergence behavior score between the Group 
BD and Group RD were comparable and was statistically not Significant. 
 
 
 Duration of Analgesia 
Group 
Mean(mins) 
P'value 
 
Estimate S.E CI  
BD 549.667 4.661 
 -115.769 - 
-85.231 
<0.001 
 
RD 650.167 6.039   Significant 
 
 
                       In our study the mean duration of analgesia in group BD was 
549.66 ± 4.6 mins, whereas in group RD was 650.16 ± 6.039 , which was 
statistically highly significant. (p< 0.001). 
 
FLACC SCORE OF GROUP  BD   AND GROUP  RD 
FLACC 
BD Group RD Group 
Mean  SD Mean  SD 
30 MINS 1.59 0.209 1.4 0.176 
1 Hr 1.797 0.161 1.6 0.138 
2 Hr 2.207 0.229 2.1 0.276 
4 Hr 2.45 0.204 2.3 0.199 
6 Hr 3.67 0.178 2.89 0.18 
8 Hr 4.2 0.191 3.02 0.187 
10 Hr 5.6 0.149 4.4 0.157 
12 Hr 6.32 0.146 5.98 0.117 
 
 
             There was a significant difference between the groups in the 
FLACC score measured 2
nd
 hourly in the post operative period. Group 
BD children achieved FLACC score of  4 at 8
th
 hr whereas Group RD 
children achieved FLACC score of  4 at 10
th
 hr. 
Post operative complications 
Post op. Complication BD Group RD Group 
PONV 2 1 
Respiratory depression Nil Nil 
Urinary retention 3 2 
Hypotension Nil Nil 
Bradycardia Nil Nil 
PONV: Post Operative Nausea and Vomiting 
 
                     In our study 3 cases had urinary retention in BD Group and 2 
cases  in RD group.2cases in BD group had vomiting and 1 case in RD group 
had vomiting. No episodes of clinically significant postoperative 
complications such as, respiratory depression, hypotension and bradycardia 
were observed. 
          
DISCUSSION 
 
         Motor blockade resulting from caudal block is very distressful to children in 
the postoperative period and delays hospital discharge. Ropivacaine in comparison 
to bupivacaine, has a wider margin of safety, less motor blockade, less 
cardiovascular /neurological toxicity and similar duration of analgesia. It can be 
safely used for regional anaesthesia and analgesia in the ambulatory setting in 
paediatrics.
,64,65,66,67
 
           Our study showed that a single pre-surgical caudal injection of ropivacaine 
after induction of anaesthesia provided good quality analgesia of sufficient duration 
following lower abdominal and perineal surgeries. 
            Ropivacaine has been used in different concentrations for caudal block with 
varying efficacy. Da Conceicao et al
68 
 used ropivacaine 0.375% for caudal block 
and found that it produces sufficient analgesia for lower abdominal surgery in 
children. But, Ivani et al 
69,70 
 in two different studies observed that 0.2% 
ropivacaine given through the caudal route in children is sufficient to provide 
sensory blockade for infra-umbilical surgeries. In our study, we used 0.25% 
ropivacaine that provided reliable and long duration analgesia. This finding is in 
conjunction with previous studies .
71,72
 
           Many workers
 
 had observed that 1ml/kg of 0.2% ropivacaine and 0.25% 
bupivacaine by caudal block had similar onset and duration. They compared these 
concentrations in order to achieve equal volumes and to maintain blindness of 
the study. But, we used equal volumes of0.25% concentration of both 
ropivacaine and bupivacaine, thereby achieving study blinding as done by 
Khalil et al 
72
 and others 
71.
 
             G.Ivani et al 
70 
 found that the mean onset time of caudal 0.2% 
ropivacaine was 9 min with that of 12 min for 0.25% bupivacaine whereas 
another study 
69 
 had observed that the mean onset time was 9.7 and 10.4 min 
respectively. T.L.Ala-Kokko et al 
73
 had evaluated that 1ml/kg of 0.2% 
ropivacaine (2mg/kg) and 0.2% bupivacaine (2mg/kg) given by caudal route 
in 30 children aged 2.3 to 8.7 years resulted in peak plasma concentrations of 
1.22 μg/ml and 1.28 μg/ml respectively which is much less than the 
maximum tolerated venous concentrations of ropivacaine (2.2(0.8) and 
bupivacaine (2.1 +-1.2) in adult volunteers.
74
 They also observed that the 
time taken to achieve peak concentrations were significantly longer for 
ropivacaine than bupivacaine indicating slower absorption and tissue 
distribution of the former after caudal administration. This difference may be 
due to the intrinsic vasoconstrictor effect of ropivacaine at low concentrations 
and higher lipid solubility of bupivacaine. In our study, we used 0.75ml/kg of 
0.25% ropivacaine, i.e.1.875 mg/kg of ropivacaine that is much less than that 
used in the above study. This obviated the need for measuring plasma 
concentration in our study. 
              In our study, the mean time from caudal block to first dose of 
diclofenac administration was comparable for both the groups with the 
average being slightly less than 6 hours. A similar trial
72
 using 0.25%  
bupivacaine or 0.25% ropivacaine showed that postoperative analgesia was 
required at a mean time of 11hours for both drugs whereas another study 
68
 
using 0.375% bupivacaine or ropivacaine revealed that the mean time for first 
analgesia was around 5 hours in both drugs. On the contrary, Ivani et al
70
 
compared 0.2% ropivacaine with 0.25% bupivacaine and observed that first 
requirement of rescue analgesia was 253 and 520 min for bupivacaine and 
ropivacaine groups respectively(P<0.05). But this finding was not replicated 
by other studies.
69,71,72.
 
           Our study showed that significant motor block was demonstrated in all 
our study children in the recovery room, with the ropivacaine group having a 
statistically significant greater motor power score than bupivacaine group. 
This faster resolution of motor blockade in the ropivacaine group continued 
in the post-operative ward also. This is in conjunction with other studies
71
 
that recorded quicker motor recovery with 0.25% ropivacaine than 0.25% 
bupivacaine. Khalil et al
72
 also found delayed motor recovery in both the 
groups and found that those who received 0.25% ropivacaine had slightly 
higher mean motor score at the end of 3 hours than those who had received 
0.25% bupivacaine. 
        Da Conceicao et al
68
 used a higher concentration (0.375%) of 
ropivacaine and bupivacaine and observed that there was significant 
difference between ropivacaine and bupivacaine groups in motor block 
postoperatively with lesser blockade in the former. This quicker motor 
recovery in ropivacaine group may be due to its less lipid solubility as 
determined by the N-heptane/buffer partition coefficient of 2.9 as against that 
of 10 for bupivacaine. This low lipid solubility and high pKa (8.1) of 
ropivacaine causes blockade of A – delta and C fibers supplying pain and 
touch sensation to a greater extent than that of the A-α and A-β fibers 
supplying motor sensation. 
              In our study, there was a delay in micturition of around five and half 
hours in both the groups with no significant difference between them. This 
was supported by others 
72 
 who did not find any difference in the time to first 
micturition between ropivacaine and bupivacaine. This delay may be due to 
the blockade of the sacral fibres caused by caudal block that prevents voiding 
of urine. 
           Only one child in ropivacaine and 2 children in bupivacaine group had 
vomiting postoperatively that was treated with Inj. Ondansentron 0.01mg/kg 
i.v. This may be due to the effects of general anaesthestics. Due to the smaller 
study group, we did not encounter any instance of intravenous or intraosseous 
injections that could have resulted in local anaesthetic toxicity, thereby 
conferring an added advantage for ropivacaine in terms of increased safety 
profile. 
          Our study and others 
69,70,72 
 have compared the effects of caudal 
ropivacaine and bupivacaine when administered along with volatile 
anaesthetics intraoperatively. Pablo M. Ingelmo et al 
75 
 in their study 
observed that without the effects of volatile anaesthetics, 0.2% ropivacaine is 
less effective during surgical stimulation than 0.2% bupivacaine and 0.2% 
levobupivacaine when used for caudal block. They reasoned out this finding 
based on the observation that all volatile anaesthetics depress the spinal 
alpha-motor neuron activity and may potentiate caudal ropivacaine. But they 
too observed that there was no difference in the analgesic onset times or 
residual analgesia indicating ropivacaine is an effective local anaesthetic. 
           Like clonidine 
76,77
, dexmedetomidine also enhances the effects of 
local anaesthetics without increasing the incidence of side effects
78
. A major 
advantage of dexmedetomidine is its higher selectivity compared with 
clonidine for α2A receptors which is responsible for the hypnotic and 
analgesic effect. Dexmedetomidine, although currently available for i.v. use 
only, has been successfully administered epidurally for postoperative 
analgesia in humans in clinical trials. 
       Bock et al.
21 
 studied the effect of clonidine on EA in 80 children aged 
3–8 years undergoing minor day-case surgery who were anesthetized with 
sevoflurane. The children received a caudal block for perioperative pain 
relief. A dose of 3 µg/kg clonidine was found to prevent agitation whether 
administered IV or caudally. In the present study using caudal 
dexmedetomidine 2 µg/kg with sevoflurane anaesthesia, the emergence 
behaviour score was less. This showed that caudally administered 
dexmedetomidine prevented the emergence agitation following sevoflurane 
significantly. 
        Saadawy et al
14
 compared caudal bupivacaine 0.25% with 
dexmedetomidine 1µg/kg and caudal bupivacaine alone and showed that the 
incidence of agitation following sevoflurane anesthesia was significantly 
lower with dexmedetomidine ( P < 0.05 ); The duration of analgesia was 
significantly longer with dexmedetomidine( P < 0.001); No statistically 
significant difference in hemodynamics between both groups; 
Dexmedetomidine had better quality of sleep and a prolonged duration of 
sedation(P < 0.05). This study showed that caudal dexmedetomidine 2 µg/kg 
with 0.25% Ropivacaine also has similar results like Saadawy et al. 
         Neogi M et al 
13
 compared Clonidine 1 µg/kg and Dexmedetomidine 
1 µg/kg as an adjuncts to Ropivacaine 0.25% for caudal analgesia in 
paediatric patients and concluded that addition of both clonidine and 
dexmedetomidine with ropivacaine administered caudally, significantly 
increases the duration of analgesia. The patients stay haemodynamically 
stable and there are no undue side effects. 
 
  
 
                 
 SUMMARY 
 
               Bupivacaine is the most frequently used local anaesthetic for caudal 
anaesthesia in children that provides reliable and long-lasting anaesthesia and 
analgesia. Ropivacaine provides pain relief similar to bupivacaine with less motor 
blockade and being a pure S-enantiomer is less cardiotoxic than the latter. 
               The aim of the study was to compare Caudal Ropivacaine 0.2% with 
Dexmedetomidine and caudal Bupivacaine 0.25% with dexmedetomidine  in terms 
of the quality, onset and duration of analgesia, motor and sensory block 
infraumbilical surgeries. 
                In a double-blinded comparative study, 60 children aged 1-6 years of 
ASA I or II physical status were randomly allocated to receive a single presurgical 
caudal injection of 1ml/kg of either 0.2% Ropivacaine (Group RD) with 
dexmedetomidine 1µg/kg or 0.25% Bupivacaine (Group BD) with 
dexmedetomidine 1µg/kg after induction of general anaesthesia. Apart from 
monitoring the vital parameters, all children were assessed for postoperative 
analgesia by FLACC scale and for motor blockade by Modified bromage scale.  
                 The groups were comparable for age, sex, weight, vital signs, duration 
and type of surgery. The quality and duration of postoperative pain relief  differ 
between the two groups (549.66 ± 4.6 min in group BD Vs 650.16 ± 6.03min in 
group RD). The motor blockade was significantly less in ropivacaine group than in 
bupivacaine group. Postoperative vitals were stable in all the children and No 
adverse events occurred during the study. 
  
              Ropivacaine is a safe and effective local anaesthetic for paediatric caudal 
anaesthesia. Ropivacaine 0.2% 1ml/kg with dexmedetomidine 1µg/kg provided 
good quality and adequate duration of analgesia than to bupivacaine 0.25% 1ml/kg 
with dexmedetomidine 1µg/kg  when administered for caudal block for 
infraumbilical surgeries. Ropivacaine produced significantly faster motor recovery 
than bupivacaine giving a distinct advantage over the latter by allowing the children 
to be discharged earlier. 
 
  
       
 
 
 
 
 
   
CONCLUSION 
 
 
            Caudal Ropivacaine with dexmedetomidine provide long lasting 
analgesia than bupivacaine with dexmedetomidine. Ropivacaine caused less 
motor blockade than bupivacaine. These along with the lower intrinsic 
toxicity of ropivacaine make it an effective and safe drug for day case surgery 
in paediatric patients. 
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1 arundoss 36 M 10 30027 PVSL 100 81 99 86 88 90 94 89.5 70 70 73 73 71.5 100 100 99 98 99.25
2 mahesh 72 M 20 30692 PVSL 88 83 100 78 80 80 80 79.5 75 75 74 74 74.5 100 100 99 99 99.50
3 mohammed kasim 36 M 14 30509 urethroplasty 96 75 100 86 88 90 92 89.0 69 69 71 71 70.0 99 100 99 100 99.50
3 dhanush 12 M 9 31230 herniotomy 104 73 100 90 92 94 94 92.5 67 67 69 69 68.0 99 100 99 100 99.50
5 azeem 48 M 15 31918 herniotomy 90 76 100 80 82 82 84 82.0 70 70 69 69 69.5 99 100 100 99 99.50
6 mahesh 72 M 15 34190 herniotomy 92 83 99 76 78 80 84 79.5 72 72 73 73 72.5 99 100 100 99 99.50
7 VIGNSEH 72 M 18 32404 herniotomy 88 73 99 74 75 77 80 76.5 67 67 69 69 68.0 100 99 100 100 99.75
8 jegannathan 48 M 10 32260 urethroplasty 96 78 100 84 86 86 88 86.0 69 69 69 69 69.0 100 99 100 100 99.75
9 vasanthan 48 M 12 34005 orchidopexy 104 72 100 84 84 85 86 84.8 69 69 73 73 71.0 100 100 99 100 99.75
10 sathish 60 M 16 34243 herniotomy 100 81 100 90 94 94 96 93.5 73 73 77 77 75.0 100 100 99 100 99.75
11 veni 36 F 10 20104 herniotomy 98 73 99 88 90 90 92 90.0 69 69 68 68 68.5 99 100 99 100 99.50
12 rakesh 30 M 9 20667 PVSL 104 73 99 88 90 94 94 91.5 70 70 73 73 71.5 99 100 99 100 99.50
13 sujith 12 M 8 31883 circumscision 110 71 99 90 92 92 94 92.0 67 67 67 67 67.0 99 100 98 100 99.25
14 kaliappan 72 M 18 30694 orchidopexy 90 80 99 76 78 78 80 78.0 69 69 71 71 70.0 100 100 99 100 99.75
15 meenatchi 12 F 8 29533 circumscision 110 72 99 98 98 99 99 98.5 65 65 67 67 66.0 100 100 100 100 100.00
16 immanuvel 12 M 16 35796 orchidopexy 100 72 98 90 92 94 94 92.5 69 69 70 70 69.5 100 100 100 99 99.75
17 vaishnavi 24 F 10 28410 herniotomy 104 73 99 96 98 98 100 98.0 69 69 70 70 69.5 100 100 100 99 99.75
18 vijaya 12 F 6.5 36376 herniotomy 110 69 99 94 94 96 98 95.5 67 67 68 68 67.5 99 99 100 99 99.25
19 vinoth 12 M 8 36398 circumscision 108 75 100 92 94 94 96 94.0 69 69 70 70 69.5 99 100 99 99 99.25
20 dhanush 72 M 18 36734 circumscision 90 83 100 76 78 78 84 79.0 72 72 73 73 72.5 99 100 98 99 99.00
21 vikatan 24 M 10 37456 PVSL 102 73 100 90 92 92 96 92.5 70 70 71 71 70.5 100 100 99 100 99.75
22 vedavalli 72 F 18 38467 herniotomy 90 83 100 84 86 86 88 86.0 74 74 75 75 74.5 100 99 99 100 99.50
23 sukumaran 12 M 10 38090 orchidopexy 108 72 100 90 94 96 98 94.5 69 69 70 70 69.5 100 100 99 100 99.75
24 vishal 36 M 11 39616 herniotomy 100 74 100 88 90 92 92 90.5 70 70 70 70 70.0 99 100 99 100 99.50
25 bharath 24 M 11 38569 PVSL 104 73 99 90 92 94 96 93.0 69 69 69 69 69.0 99 100 99 99 99.25
26 esakkimuthu 72 M 17 39001 circumscision 88 83 99 75 77 78 80 77.5 73 73 74 74 73.5 100 100 100 99 99.75
27 albert 60 M 16 40384 PVSL 96 75 100 86 88 90 92 89.0 69 69 71 71 70.0 100 99 100 99 99.50
28 david 18 M 7 38998 herniotomy 104 73 100 88 90 94 94 91.5 70 70 73 73 71.5 100 99 100 99 99.50
29 mansiya 24 M 9 40527 herniotomy 108 72 100 90 94 96 98 94.5 69 69 70 70 69.5 100 99 100 100 99.75
30 maharajan 36 M 10 40705 circumscision 100 74 99 88 90 92 92 90.5 70 70 70 70 70.0 100 99 100 100 99.75
INTRAOPPRE OP
SpO2PR MAP
EOS
DOS(in 
mins)
emergence 
time (in 
mins)
emergence 
behaviour 
Score
PR MAP SpO2 2 4 6 8 12 Avg Avg 2 4 6 8 12
86 70 97 40 5 5 86 88 90 94 94 90.40 90/60 70 96/62 73 98/62 74 100/60 73 100/60 73 72.60 99 99 97 99 100
78 75 98 40 4 5 78 80 80 80 80 79.60 100/62 75 102/60 74 102/62 75 104/62 76 104/68 80 76.00 99 99 98 99 100
86 69 98 95 5 3 86 88 90 92 92 89.60 90/58 69 94/60 71 96/60 72 96/62 73 100/60 73 71.60 99 98 98 99 100
90 67 99 40 6 4 90 92 94 94 94 92.80 90/56 67 92/58 69 92/60 71 92/62 73 92/60 71 70.20 99 98 99 99 99
80 70 100 60 5 5 80 82 82 84 84 82.40 90/60 70 92/60 69 92/60 71 92/62 73 92/64 73 71.20 99 97 100 99 99
76 72 100 40 4 6 76 78 80 84 84 80.40 96/60 72 96/62 73 98/62 74 100/62 75 100/62 75 73.80 100 100 100 100 98
74 67 99 35 3 3 74 75 77 80 80 77.20 90/56 67 90/58 69 92/60 71 94/60 71 94/60 71 69.80 99 99 99 99 99
84 69 98 60 4 3 84 86 86 88 90 86.80 90/58 69 92/60 69 92/60 71 94/60 71 94/60 71 70.20 99 99 98 99 99
84 69 99 45 3 5 84 84 85 86 88 85.40 92/60 69 92/62 73 94/60 71 98/60 73 100/60 73 71.80 99 100 99 99 99
90 73 99 40 4 3 90 94 94 96 98 94.40 100/60 73 104/64 77 104/62 76 102/70 81 104/70 81 77.60 99 98 99 99 99
88 69 99 80 5 3 88 90 90 92 93 90.60 88/56 69 88/58 68 90/58 69 90/58 69 90/60 70 69.00 100 99 99 100 99
88 70 99 45 4 3 88 90 94 94 96 92.40 90/60 70 94/62 73 98/60 73 98/60 73 98/60 73 72.40 100 99 99 100 100
90 67 97 30 5 4 90 92 92 94 96 92.80 86/58 67 88/56 67 88/60 69 90/60 70 90/60 70 68.60 100 99 97 100 100
76 69 98 40 3 3 76 78 78 80 84 79.20 92/60 69 94/60 71 98/62 74 100/60 73 102/60 74 72.20 100 99 98 100 100
98 65 99 30 5 3 98 98 99 99 100 98.80 88/54 65 88/56 67 90/58 69 90/58 69 92/60 71 68.20 100 99 99 100 99
90 69 99 35 3 3 90 92 94 94 96 93.20 90/58 69 90/60 70 92/60 71 94/60 71 94/60 71 70.40 99 100 99 99 99
96 69 100 40 4 4 96 98 98 100 102 98.80 92/58 69 90/60 70 92/60 71 94/60 71 96/60 72 70.60 99 100 100 99 98
94 67 100 35 5 3 94 94 96 98 105 97.40 86/58 67 88/58 68 88/60 69 90/58 69 90/58 69 68.40 99 100 100 99 98
92 69 100 35 5 3 92 94 94 96 98 94.80 90/58 69 90/60 70 92/60 71 94/60 71 94/60 71 70.40 99 100 100 99 100
76 72 100 40 4 5 76 78 78 84 84 80.00 96/60 72 98/60 73 100/60 73 100/62 75 106/60 75 73.60 100 99 100 100 100
90 70 99 45 5 5 90 92 92 96 98 93.60 90/60 70 92/60 71 94/60 71 94/60 71 94/60 71 70.80 99 99 99 99 99
84 74 98 40 6 3 84 86 86 88 88 86.40 98/62 74 98/64 75 100/64 75 100/66 77 100/70 80 76.20 100 99 98 100 99
90 69 97 45 5 4 90 94 96 98 100 95.60 90/58 69 90/60 70 92/60 71 92/60 71 94/60 71 70.40 99 98 97 99 99
88 70 97 30 4 3 88 90 92 92 94 91.20 94/58 70 94/58 70 96/60 72 98/60 73 98/60 73 71.60 99 99 97 99 99
90 69 98 50 3 3 90 92 94 96 98 94.00 90/58 69 92/58 69 92/60 71 92/60 71 94/60 71 70.20 100 99 98 100 100
75 73 99 30 4 3 75 77 78 80 80 78.00 100/60 73 102/60 74 102/62 75 104/60 73 104/60 73 73.60 100 99 99 100 100
86 69 100 95 5 3 86 88 90 92 92 89.60 90/58 69 94/60 71 96/60 72 96/62 73 100/60 73 71.60 99 99 100 99 100
88 70 100 45 5 3 88 90 94 94 96 92.40 90/60 70 94/62 73 98/60 73 98/60 73 98/60 73 72.40 99 100 100 99 100
90 69 97 45 6 4 90 94 96 98 100 95.60 90/58 69 90/60 70 92/60 71 92/60 71 94/60 71 70.40 99 100 97 99 99
88 70 98 30 5 2 88 90 92 92 94 91.20 94/58 70 94/58 70 96/60 72 98/60 73 98/60 73 71.60 98 99 98 98 99
SpO2
2 4 6 128
PR MAP
Total duration 
of analgesia 
mins
Motor 
Power 
(mins)
Full Sensory 
Recovery 
(mins)
Onset of 
action in 
min
Avg 2 4 6 8 12 30 min 1 2 4 6 8 10 12 0 MINS 5 MINS 10 MINS 15 MINS 20 MINS 25 MINS 30 MINS
98.8 3 3 2 2 2 1.8 1.7 2.2 3.6 5.6 6.6 7.6 6.9 575 126 129 124 119 115 108 111 155 60 6.8
99.0 3 3 2 2 2 1.4 2.0 2.4 4.0 5.3 6.5 7.4 6.9 530 116 122 116 111 108 101 103 165 90 6.8
98.8 3 3 2 2 2 1.5 1.6 2.3 3.5 5.6 6.8 7.5 6.8 555 124 127 122 117 110 103 102 160 75 6.8
98.8 3 3 2 2 2 1.6 2.0 2.4 3.7 5.2 6.4 7.2 6.9 550 133 126 121 115 110 105 105 130 85 6.6
98.8 3 3 2 2 2 1.2 1.7 2.2 3.5 5.6 6.8 7.4 6.8 510 127 121 116 110 108 101 104 145 65 6.9
99.6 3 3 2 2 1 1.8 1.9 2.1 3.6 5.3 6.5 7.3 7.2 525 134 126 122 117 109 108 103 160 90 6.4
99.0 3 3 2 3 1 1.5 2.0 2.3 4.0 5.6 6.4 7.4 6.9 510 136 129 124 119 110 103 104 155 60 6.5
98.8 3 3 2 2 1 1.8 1.7 2.4 3.7 5.4 6.8 7.6 6.9 515 123 115 112 116 112 107 110 175 70 6.7
99.2 3 3 2 2 1 1.5 2.0 2.0 4.0 5.6 6.3 7.6 6.9 525 121 112 109 104 110 104 106 170 75 6.9
98.8 3 3 2 2 2 1.8 1.8 2.2 3.5 5.3 6.8 7.2 6.8 520 137 132 127 122 110 102 105 140 80 6.4
99.4 3 3 2 2 2 1.7 1.6 2.3 3.7 5.2 6.4 7.3 7.2 530 132 126 122 116 109 103 106 165 85 6.7
99.6 3 3 2 2 1 1.8 1.7 2.3 3.5 5.2 6.5 7.6 6.8 530 133 128 121 115 107 101 105 180 65 6.5
99.2 3 3 2 2 1 1.3 1.6 2.1 3.6 5.6 6.5 7.4 6.9 535 143 128 128 122 111 117 106 145 90 6.6
99.4 3 3 2 2 1 1.8 1.7 2.1 3.5 5.3 6.8 7.5 6.9 530 131 127 121 116 115 111 105 160 65 6.8
99.4 3 3 2 2 1 1.6 1.8 2.3 4.0 5.6 6.4 7.6 7 535 124 118 113 108 114 112 103 175 70 6.9
99.2 3 3 2 2 1 1.4 1.9 1.2 3.5 5.2 6.3 7.3 6.9 540 123 116 112 105 105 118 106 135 75 6.7
99.2 2 3 2 2 1 1.8 2.0 2.2 3.7 5.6 6.8 7.4 7.2 555 132 126 121 116 116 112 106 120 90 7.2
99.2 3 3 2 2 1 1.5 1.7 2.0 4.0 5.3 6.6 7.5 6.8 540 135 128 123 115 107 106 104 145 65 6.4
99.6 3 3 2 2 1 1.7 1.6 2.4 3.5 5.2 6.8 7.2 6.9 575 137 128 129 124 112 101 109 120 70 7.3
99.8 3 3 2 2 2 1.8 1.6 2.2 3.6 5.2 6.8 7.6 6.8 550 135 129 124 119 107 107 104 140 75 6.7
99.0 3 3 2 2 2 1.8 2.0 2.1 4.0 5.6 6.4 7.3 6.9 600 126 119 115 108 110 113 102 155 80 7.1
99.2 3 3 2 2 1 1.2 1.7 2.4 3.7 5.3 6.5 7.4 6.8 575 122 115 112 105 114 112 106 145 85 6.7
98.4 3 3 2 2 1 1.8 1.9 2.3 3.5 5.6 6.8 7.6 7.2 575 132 124 119 114 110 104 105 150 65 6.6
98.6 3 3 2 2 1 1.5 2.0 2.2 3.5 5.2 6.7 7.2 6.9 565 134 128 123 118 113 109 106 125 90 6.6
99.4 3 3 2 2 1 1.6 1.8 2.1 3.6 5.3 6.8 7.4 7 600 131 127 122 117 112 110 101 135 65 6.5
99.6 3 3 2 2 1 1.2 2.0 2.4 3.5 5.6 6.3 7.6 7.1 580 124 118 113 118 108 108 104 150 70 6.9
99.4 3 3 2 2 1 1.7 1.6 2.4 4.0 5.6 6.4 7.2 7.2 550 133 126 121 116 114 104 106 155 90 6.8
99.6 3 3 2 2 1 1.5 2.0 2.2 3.5 5.6 6.5 7.6 7.2 560 124 129 122 116 107 105 112 140 65 6.6
98.8 3 3 2 2 2 1.3 1.7 2.1 3.7 5.2 6.8 7.4 6.8 570 124 118 113 114 112 119 104 150 70 6.5
98.4 3 3 2 2 1 1.8 1.6 2.4 4.0 5.3 6.8 7.6 6.9 580 132 129 124 119 115 113 109 160 75 6.3
SEDATION FLACC HEART RATE
RD GROUP
SNO NAME AGE SEX
WEIGHT 
in KGs IP no TYPE OF SURGERY
PR MAP spo2 5Min 10MIN 20MIN 30MIN Avg 5MIN 10MIN 20MIN 30MIN Avg 5MIN
1 madan gopal 72 M 15 34568 urethroplasty 94 75 99 76 78 79 81 78.50 75 76 77 78 76.50 98
2 sethupathy 60 M 15 34589 orchiopexy 98 83 100 80 82 83 84 82.25 75 76 77 77 76.25 99
3 jeevanathan 12 M 10 33584 circumscision 104 72 100 88 90 92 96 91.50 68 66 67 69 67.50 100
4 balajothi 72 M 15 32934 PVSL 98 84 100 90 90 92 94 91.50 78 79 79 79 68.25 100
5 karthick 24 M 8 32430 circumscision 105 76 100 90 94 96 98 94.50 72 72 73 74 72.75 99
6 manthiramoorthy 72 M 15 31901 circumscision 98 74 99 80 82 86 88 84.00 79 80 81 81 70.25 99
7 ajay 72 M 15 31737 orchiopexy 97 73 99 86 88 90 92 89.00 70 68 70 71 69.75 100
8 esakkimuthu 36 M 8 31195 PVSL 90 83 100 90 86 86 88 87.50 78 75 74 75 75.50 100
9 tharunraj 72 M 15 30644 orchiopexy 86 72 100 86 84 87 86 85.75 70 68 70 72 70.00 100
10 kavibalan 48 M 15 30472 PVSL 100 81 100 100 98 99 96 98.25 75 74 77 78 76.00 100
11 suganthi 12 F 8 30022 herniotomy 92 83 99 94 92 90 92 92.00 72 74 75 76 74.25 100
12 pathirakali 60 M 9 29377 herniotomy 82 73 99 90 86 84 80 85.00 76 75 78 80 69.25 100
13 ashiq 12 M 8.5 35765 circumscision 98 81 99 90 92 90 90 90.50 74 76 74 77 75.25 100
14 ganeshamoorthy 60 M 14 29736 urethroplasty 98 80 99 102 101 100 101 101.00 75 76 78 80 77.25 100
15 thirumalai 72 M 17 34831 urethroplasty 98 73 99 98 98 99 99 98.50 68 68 69 70 68.75 100
16 nithish kumar 36 M 8 36400 herniotomy 100 75 98 100 100 98 99 99.25 68 69 68 70 68.75 99
17 thayubala 12 M 8 36389 herniotomy 104 73 99 102 100 101 102 101.25 66 68 69 70 68.25 99
18 guna 72 M 13 34830 PVSL 96 77 99 94 92 94 94 93.50 67 68 69 70 68.50 99
19 sakthivel 24 M 17 36847 circumscision 94 75 100 94 92 92 94 93.00 69 70 72 72 70.75 99
20 rahul 48 M 15 37510 circumscision 106 73 100 106 104 106 108 106.00 69 70 71 72 70.50 99
21 poovarasan 72 M 17 37948 herniotomy 98 81 100 90 90 92 94 91.50 78 77 79 80 69.50 100
22 ganeshamoorthy 60 M 14 29736 herniotomy 98 80 100 102 101 100 101 101.00 75 72 76 77 75.00 100
23 saravanan 42 M 14 38598 herniotomy 98 72 100 90 86 86 88 87.50 75 76 78 78 69.75 100
24
subash 
chandrabose 36 M 10 39466 herniotomy 104 72 100 88 90 92 96 91.50 65 67 68 69 67.25 100
25 karuppasamy 24 M 15 39277 urethroplasty 98 81 99 76 78 79 81 78.50 74 76 77 78 76.25 99
26 maria nishanth 36 M 12 37853 circumscision 104 72 99 88 90 92 96 91.50 66 65 68 69 67.00 99
27 uthandaraman 48 M 13 46358 PVSL 94 71 100 90 90 92 94 91.50 74 75 76 78 75.75 99
28 rajesh kumar 72 M 19 40694 herniotomy 94 72 100 90 90 92 94 91.50 74 72 77 76 74.75 99
29 abishkumar 36 M 12 40690 circumscision 104 72 100 88 90 92 96 91.50 65 64 67 68 66.00 100
30 esakkidurai 60 M 12.5 40687 herniotomy 94 81 99 90 90 92 94 91.50 75 77 78 80 77.50 100
PR MAP
PREOP
INTRAOP

EOS DOS(in 
mins)
Emergence 
time
emergence 
behavour 
score
PR MAP SpO2 time SCORE 2 4 6 8 12 Avg 2 4 6 8 12 Avg 2 4 6 8 12 Avg 2 4 6 8 12
10MIN 20MIN Avg
99 100 99.00 76 78 100 70 5 3 76 78 79 81 82 79.20 74 77 76 81 81 78.20 97 99 99 97 99 98.20 3 3 2 1 1
99 100 99.33 78 78 100 45 4 4 80 82 83 84 86 83.00 73 75 75 80 82 67.00 98 99 99 98 99 98.60 3 3 2 2 2
99 100 99.67 88 70 100 30 5 3 88 90 92 96 98 92.80 70 71 71 72 73 71.40 98 99 98 98 99 98.40 3 3 2 2 1
99 100 99.67 90 80 99 35 6 4 90 90 92 94 94 92.00 73 73 74 77 79 75.20 99 99 98 99 99 98.80 3 3 2 2 2
100 100 99.67 90 76 99 30 5 3 90 94 96 98 100 95.60 71 72 74 75 76 73.60 100 99 97 100 99 99.00 3 2 2 2 1
100 100 99.67 80 82 98 35 4 3 80 82 86 88 90 85.20 75 79 81 82 83 69.40 100 100 100 100 100 100.00 3 3 2 2 1
100 99 99.67 88 72 99 45 6 3 86 88 90 92 92 89.60 73 75 73 76 79 75.20 99 99 99 99 99 99.00 3 3 2 2 2
100 99 99.67 88 76 99 35 4 3 90 86 86 88 90 88.00 83 81 82 81 83 69.25 98 99 99 98 99 98.60 3 3 1 2 1
99 100 99.67 84 74 99 40 3 4 86 84 87 86 85 85.60 79 81 83 83 83 68.30 99 99 100 99 99 99.20 3 3 2 2 2
99 100 99.67 90 80 99 45 4 3 100 98 99 96 98 98.20 75 77 76 81 81 68.00 99 99 98 99 99 98.80 3 3 2 2 1
99 100 99.67 92 80 99 45 5 3 94 92 90 92 93 92.20 89 89 86 89 90 70.10 99 100 99 99 100 99.40 3 3 2 2 2
99 100 99.67 82 84 100 80 4 3 90 86 84 80 82 84.40 85 81 83 85 87 70.30 99 100 99 99 100 99.40 3 3 2 2 1
98 100 99.33 90 78 100 35 5 3 90 92 90 90 92 90.80 83 78 76 80 79 69.21 97 100 99 97 100 98.60 3 3 2 2 2
99 100 99.67 100 80 100 40 6 4 102 101 100 101 100 100.80 73 73 74 73 74 73.40 98 100 99 98 100 99.00 2 3 2 2 1
100 100 100.00 100 70 99 90 5 3 98 98 99 99 98 98.40 73 73 73 73 73 73.00 99 100 99 99 100 99.40 3 3 2 2 1
100 100 99.67 100 70 99 35 3 3 100 100 98 99 99 99.20 74 73 73 73 73 73.20 99 99 100 99 99 99.20 3 3 2 2 1
100 100 99.67 103 70 98 40 3 3 102 100 101 102 100 101.00 73 73 73 73 73 73.00 100 99 100 100 99 99.60 2 3 2 1 2
100 99 99.33 96 72 98 40 5 3 94 92 94 94 92 93.20 73 73 73 73 73 67.60 100 99 100 100 99 99.60 3 3 2 2 1
99 100 99.33 96 74 100 30 5 4 94 92 92 94 94 93.20 73 73 74 73 74 73.40 100 99 100 100 99 99.60 3 3 2 2 2
98 100 99.00 108 72 100 30 4 3 106 104 106 108 106 106.00 72 73 73 73 73 72.80 100 100 99 100 100 99.80 3 2 2 2 1
99 100 99.67 95 81 99 35 5 3 90 90 92 94 94 92.00 73 73 74 77 79 75.20 99 99 99 99 99 99.00 3 3 2 2 2
99 99 99.33 102 80 99 40 3 3 102 101 100 101 100 100.80 75 73 74 73 74 73.80 98 100 99 98 100 99.00 3 3 1 2 2
99 100 99.67 90 80 99 35 5 3 90 86 86 88 90 88.00 85 81 82 81 83 71.25 97 99 98 97 99 98.00 3 3 2 2 1
99 100 99.67 98 70 99 30 4 3 88 90 92 96 98 92.80 70 71 71 72 73 71.40 97 99 99 97 99 98.20 3 3 2 2 1
99 100 99.33 83 79 100 70 3 3 76 78 79 81 82 79.20 74 77 76 81 81 67.80 98 100 99 98 100 99.00 3 3 2 2 1
100 100 99.67 98 70 100 30 6 3 88 90 92 96 98 92.80 70 71 71 72 73 71.40 99 100 99 99 100 99.40 3 3 2 2 1
100 99 99.33 96 78 100 35 5 4 90 90 92 94 94 92.00 73 73 74 77 79 75.20 100 99 99 100 99 99.40 3 3 2 2 1
100 99 99.33 96 79 100 35 5 4 90 90 92 94 94 92.00 73 73 74 77 78 75.00 100 99 100 100 99 99.60 3 3 2 2 2
100 99 99.67 95 69 99 30 6 3 88 90 92 96 98 92.80 70 71 71 72 73 71.40 97 99 100 97 99 98.40 3 3 2 2 1
100 99 99.67 95 81 99 35 5 4 90 90 92 94 94 92.00 73 73 74 77 78 75.00 98 98 99 98 98 98.20 3 3 2 2 1
SEDATION
POST OPERATPOST OPERATIVE PERIOD (HOURS)
PR
SpO2
MAP SpO2
Total duration 
of analgesia 
hrs
30 min 1 2 4 6 8 10 12
1.6 1.8 2.0 3.6 5.2 6.6 8.8 6.9 655 0 MINS 5 MINS 10 MINS 15 MINS 20 MINS 25 MINS 30 MINS
1.3 1.7 2.6 3.9 5.7 6.5 8.6 6.9 615 129 124 124 119 113 110 106 125 65 6.4
1.8 1.8 2.1 3.6 5.6 6.8 8.4 6.8 620 119 127 120 115 113 102 105 135 70 6.7
1.5 1.9 2.4 4.0 5.3 6.8 8.8 6.9 690 127 124 122 117 112 104 106 130 65 6.3
1.6 2 2.3 3.7 5.6 6.8 8.5 6.8 630 136 123 124 115 108 106 101 100 60 6.8
1.2 1.9 2.6 3.5 5.6 6.9 8.5 6.6 700 131 124 119 113 116 103 104 115 75 6.5
1.8 1.6 2.5 3.9 5.6 6.4 8.4 6.9 640 137 129 122 117 110 110 106 130 80 6.6
1.7 1.9 2.4 3.9 5.7 6.8 8.8 6.9 665 139 131 124 119 108 105 108 135 75 6.6
1.8 2 2.4 3.6 5.2 6.9 8.4 6.9 650 126 121 118 116 116 109 104 150 60 6.8
1.5 1.7 2.2 4.0 5.4 6.8 8.6 6.8 620 124 128 116 124 108 106 109 135 90 6.3
1.8 1.9 2.6 3.5 5.6 6.8 8.4 6.6 670 130 125 127 122 109 103 111 110 95 6.6
1.7 2 2.4 3.7 5.3 6.6 8.8 6.8 635 136 126 122 116 107 104 103 135 90 6.8
1.8 1.8 2.4 3.9 5.7 6.9 8.5 6.9 680 135 128 124 115 105 102 102 140 60 6.8
1.8 2 2.0 4.0 5.2 6.8 8.8 6.9 700 147 128 128 122 109 119 105 115 110 6.7
1.8 1.6 2.2 4.0 5.3 6.4 8.5 7 690 134 127 122 116 107 112 104 130 65 6.8
1.6 2 2.6 3.7 5.6 6.3 8.5 6.9 700 127 123 116 112 105 113 103 145 90 6.5
1.4 1.7 2.3 4.0 5.6 6.8 8.6 6.7 615 136 124 117 110 11 119 104 105 85 6.8
1.8 1.9 2.1 3.5 5.7 6.8 8.8 6.8 680 133 126 121 116 112 113 110 95 60 6.7
1.5 2 2.1 3.7 5.5 6.8 8.8 6.9 625 139 128 123 115 107 107 106 120 65 6.8
1.7 2 2.3 3.5 5.6 6.8 8.8 6.8 700 132 128 129 124 111 105 105 95 65 6.5
1.8 1.6 1.2 3.6 5.6 6.6 8.5 6.9 635 132 129 124 119 106 107 106 110 60 6.8
1.8 2 2.2 3.9 5.3 6.5 8.6 6.8 625 129 125 118 116 108 113 105 125 80 6.7
1.8 1.7 2.5 4.0 5.6 6.8 8.6 6.6 645 127 121 119 121 112 112 106 115 65 6.4
1.7 1.9 2.4 3.5 5.2 6.7 8.4 6.9 610 131 124 122 114 108 104 105 120 60 6.7
1.8 2 2.2 3.7 5.7 6.8 8.8 7 655 133 128 123 118 110 109 103 105 95 6.6
1.6 1.9 2.6 4.0 5.3 6.3 8.8 6.7 615 134 127 122 117 109 110 106 95 80 6.8
1.7 2 2.2 3.8 5.6 6.4 8.4 6.6 610 127 118 115 118 106 108 106 120 75 6.8
1.7 1.8 2.5 4.0 5.4 6.9 8.6 6.7 605 134 126 121 116 108 104 104 125 65 6.7
1.5 1.9 2.4 3.5 5.7 6.8 8.5 6.8 625 129 129 122 116 105 105 109 110 60 6.8
1.3 1.7 2.4 3.5 5.4 6.8 8.7 6.7 700 127 128 117 114 110 119 104 120 65 6.7
138 129 124 121 111 113 102 130 80 6.6
TIVE PERIOD (HOURS)
FLACC Motor 
Power 
(mins)
Full Sensory 
Recovery 
(mins)
Onset of 
action in 
min
HEART RATE
01
2
3
4
5
6
7
8
9
30 MINS 1 Hr 2 Hr 4 Hr 6 Hr 8 Hr 10 Hr 12 Hr
1.59 
1.797 
2.207 
3.69 
5.407 
6.593 
7.43 
6.947 
1.647 1.857 
2.303 
3.757 
5.493 
6.697 
8.607 
6.813 
FLACC SCORE COMPARISON 
Group BD Group RD
No. % No. %
 12 - 24 12 40.00 7 23.33
 25 - 36 6 20.00 5 16.67
 37 - 48 3 10.00 4 13.33
 49 - 60 2 6.67 5 16.67
 61 - 72 7 23.33 9 30.00
Total 30 100.00 30 100.00
Mean
SD
p' value
No. % No. %
MALE 25 83.33 29 96.67
FEMALE 5 16.67 1 3.33
Total 30 100.00 30 100.00
p' value
% No. %
 6 - 10 15 50.00 9 30.00
 11 - 15 6 20.00 17 56.67
 16 - 20 9 30.00 4 13.33
Total 30 100.00 30 100.00
Mean 12.317 12.9
Age in months
RD Group
47.8
21.417
BD Group
39.2
22.982
Weight in kgs
0.197  Not significant
RD Group
Sex
0.244  Not Significant
RD GroupBD Group
BD Group
SD
p' value
Mean S.D Mean S.D
Duration Of 
Surgery(mins) 45.333 17.066 41.667 15.388
Types Of Surgery BD Group RD Group
circumscision 6 8
herniotomy 12 11
PVSL 6 4
orchidopexy 4 3
urethroplasty 2 4
Total 30 30
p' value
Mean S.D Mean S.D
PR 99.4 7.262 97.467 5.501
MAP 75.6 4.344 76.333 4.373
SPO2 99.53 0.571 99.5 0.572
PR 88.708 6.357 91.675 6.564
MAP 70.283 2.204 71.767 3.657
SPO2 99.558 0.224 99.544 0.223
PR 89.487 6.443 92.093 6.363
MAP 71.58 2.246 71.967 2.837
SPO2 99.133 0.376 99.013 0.53
Pre op
Intraop
Post op
Variables
0.536 Not significant
0.82  Not significant
3.239
RD Group
BD Group
BD Group
RD Group
3.984
Variables
Mean S.D Mean S.D
Emergence Time 4.467 0.9 4.6 0.968
Emergence Behaviour 
Score 3.633 0.964 3.267 0.45
Sedation score
Mean S.D Mean S.D
2 2.967 0.183 2.9 0.305
4 3 0 2.933 0.254
6 2 0 1.9 0.305
8 2.033 0.183 1.933 0.254
12 1.333 0.479 1.367 0.49
Duration of Analgesia
Estimate S.E CI
BD 549.667 4.661  -115.769 - -85.231
RD 650.167 6.039
Mean S.D Mean S.D
0 129.467 6.107 131.933 5.514
5 124.2 5.352 125.933 2.912
Time in Hours
BD Group RD Group
<0.001
BD Group RD Group
Group
Mean(hr)
P'value
Heart Rate(mins)
RD GroupBD Group
10 119.7 5.305 121.5 3.501
15 115.033 5.055 117.1 3.346
20 110.667 2.916 106 18.181
25 107.567 5.211 108.533 4.995
30 105.4 2.608 105.267 2.348
Post op. Complication BD Group RD Group Post op. Complication
PONV 2 1 PONV
Respiratory depression Nil Nil Respiratory depressi
Urinary retention 3 2 Urinary retention
Hypotension Nil Nil Hypotension
Bradycardia Nil Nil Bradycardia
Onset of action in min
Mean S.D Mean S.D
6.707 0.236 6.653 0.157
Motor power in minutes Mean S.D Mean S.D
150.167 15.728 120.667 14.84
Full Sensory recovery 
in min BD Group RD Group
BD Group RD Group
BD Group RD Group
Mean S.D Mean S.D
75.167 10.127 73.667 13.451
Mean SD Mean SD
30 MINS 1.59 0.209 1.647 0.176
1 Hr 1.797 0.161 1.857 0.138
2 Hr 2.207 0.229 2.303 0.276
4 Hr 3.69 0.204 3.757 0.199
6 Hr 5.407 0.178 5.493 0.18
8 Hr 6.593 0.191 6.697 0.187
10 Hr 7.43 0.149 8.607 0.157
12 Hr 6.947 0.146 6.813 0.117
FLACC
BD Group RD Group
No. % Age in months Group BD Group RD
19 31.67  12 - 24 12 7
11 18.33  25 - 36 6 5
7 11.67  37 - 48 3 4
7 11.67  49 - 60 2 5
16 26.67  61 - 72 7 9
60 100.00
Sex Group BD 
No. % MALE 25
54 90.00 FEMALE 5
6 10.00
60 100.00
Sex Group RD
MALE 29
FEMALE 1
Weight in kgs Group BD Group RD
No. %  6 - 10 15 9
24 40.00  11 - 15 6 17
23 38.33  16 - 20 9 4
13 21.67
60 100.00
Total
Total
Total
Group BD 
Duration Of 
Surgery(mins) 45.333
3.666 0.874 0.874 Not significant
Difference 
Of Mean t' P'value
1.933 1.162 0.250 Not sig PR
-0.652 -0.733 0.517 Not sig MAP
0.033 0.226 0.822 Not sig SPO2
-2.967 -1.778 0.081 Not sig PR
-1.483 -1.903 0.062 Not sig MAP
0.0139 0.241 0.811 Not sig SPO2
-2.607 -1.577 0.120 Not sig PR
-4.567 -0.586 0.560 Not sig MAP
0.12 1.011 0.316 Not sig SPO2
Pre op
Intraop
Post op
p-valueDifference Of Mean t-value
Difference 
Of Mean t' P'value
Group BD 
-0.133 -0.553 0.583 Not sig Emergence Time 4.533
0.367 1.887 0.064 Not sig
Emergence 
Behaviour 
Score
1.333
P'value Significance
Sedation score Group BD Group RD
0.309 Not sig S 2 3.0 2.9
0.155 Not sig 4 3.0 2.9
0.078 Not sig 6 2.0 1.9
0.085 Not sig 8 2.0 1.9
0.791 Not sig S 12 1.3 1.4
Duration of analgesiaMean
BD 549.7
Significant RD 650.2
P'value Heart rate Group BD Group RD
H 0 129.5 131.9
0.106 Not sig 5 124.2 125.9
0.125 Not sig 10 119.7 121.5
0.126 Not sig 15 115.0 117.1
0.067 Not sig 20 110.7 106.0
0.17 Not sig 25 107.6 108.5
0.466 Not sig H 30 105.4 105.3
0.836 Not sig
BD Group RD Group
2 1
0 0
3 2
0 0
0 0
P'value Onset of action in m Group BD Group RD
Mean 6.71 6.55
0.307 Not sig
Motor power in minu Group BD Group RD
P'value Mean 150.17 120.67
<0.001 Significant
Full Sensory 
recovery in min Group BD Group RD
P'value Mean 75.17 73.67
0.627 Not Sig
FLACC Group BD Group RD
30 MINS 1.59 1.647
0.26 1 Hr 1.797 1.857
0.127 2 Hr 2.207 2.303
0.145 4 Hr 3.69 3.757
0.206 6 Hr 5.407 5.493
0.066 8 Hr 6.593 6.697
0.038 10 Hr 7.43 8.607
<0.001 12 Hr 6.947 6.813
<0.001
p' value

Group RD
41.667
Group BD Group RD
99.4 95.2
75.6 78.6
99.5 99.5
88.7 91.7
70.3 73.3
99.6 99.5
89.5 92.1
71.6 76.1
99.1 99.0
Group RD
4.633
3.467
02
4
6
8
10
12
 12 - 24  25 - 36  37 - 48  49 - 60  61 - 72
12 
6 
3 
2 
7 7 
5 
4 
5 
9 
AGE DISTRIBUTION  IN MONTHS 
Group BD Group RD
83% 
17% 
GENDER DISTRIBUTION IN GROUP BD 
MALE FEMALE
97% 
3% 
GENDER DISTRIBUTION IN  GROUP RD 
MALE FEMALE
15 
6 
9 9 
17 
4 
0
2
4
6
8
10
12
14
16
18
 6 - 10  11 - 15  16 - 20
WEIGHT COMPARISION 
Group BD Group RD
39
40
41
42
43
44
45
46
Group BD Group RD
45.333 
41.667 
Duration Of Surgery(mins) 
Group BD Group RD
99.4 
75.6 
99.53 
88.708 
70.283 
99.558 
89.487 
71.58 
99.133 
95.233 
78.6 
99.5 
91.675 
73.25 
99.544 
92.093 
76.147 
99.013 
0
20
40
60
80
100
120
PR MAP SPO2 PR MAP SPO2 PR MAP SPO2
Pre op Intraop Post op
COMPARISON OF HEMODYNAMIC VARIABLES 
GROUP BD GROUP RD
00.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Emergence Time Emergence Behaviour Score
4.533 
1.333 
4.633 
3.467 
EMERGENCE TIME 
Group BD Group RD
00.5
1
1.5
2
2.5
3
S 2 4 6 8 S 12
2.967 3 
2 2.033 
1.333 
2.9 2.933 
1.9 1.933 
1.367 
SEDATION SCORE IN HOURS 
Group BD Group RD
480
500
520
540
560
580
600
620
640
660
BD RD
549.667 
650.167 
DURATION OF ANALGESIA 
BD RD
129.467 
124.2 
119.7 
115.033 
110.667 
107.567 105.4 
131.933 
125.933 
121.5 
117.1 
106 108.533 105.267 
0
20
40
60
80
100
120
140
H 0 5 10 15 20 25 H 30
HEART RATE COMPARISON 
Group BD Group RD
00.5
1
1.5
2
2.5
3
PONV Respiratory
depression
Urinary retention Hypotension Bradycardia
2 
0 
3 
0 0 
1 
0 
2 
0 0 
COMPARISON OF POST OP COMPLICATIONS 
BD Group RD Group
6.00
6.25
6.50
6.75
7.00
Group BD Group RD
6.71 
6.55 
ONSET OF ACTION IN MINUTES 
Group BD Group RD
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
Group BD Group RD
150.17 
120.67 
MOTOR POWER IN MINUTES 
Group BD Group RD
72.50
73.00
73.50
74.00
74.50
75.00
75.50
Group BD Group RD
75.17 
73.67 
FULL SENSORY RECOVERY IN MIN 
Group BD Group RD
6 
12 
6 
4 
2 
8 
11 
4 
3 
4 
0 2 4 6 8 10 12 14
circumscision
herniotomy
PVSL
orchidopexy
urethroplasty
TYPE OF SURGERY 
RD Group BD Group
PROFORMA 
Department  of  Anaesthesiology 
Govt. Theni  Medical  College Hospital,   Theni. 
Name of the Patient :                                                        Age/ sex: 
IP No:                                                                                              Wt:       
Address :                                                                          ASA: 
 
Diagnosis :                                                                        Procedure :            
 
Time of Induction : 
Time of Intubation : 
Time of Caudal Block : 
Time of skin incision : 
End of Procedure :  
Time of extubation: 
Duration of Surgery: 
Pre-induction :  Bp:      /        ,   PR :                Spo2 :      
 
Intra-Op  [ post –induction] 
  Pulse Bp Spo2 Sevo   
% 
Fent.Dose Compli 
cations 
Treatment 
5min        
10 min        
15min        
20min        
25min        
30min        
35min        
40min        
45min        
50min        
55min        
60min        
  Behaviour during emergence :     1.calm 
                                                       2. Not calm but could be easily calmed 
                                                       3. not easily calmed, moderaltly agitated or  
                                                          restless 
                                                                  4. combative, excited or disoriented   
Post Op 
 HR BP Pain Sedation Motor 
blockade 
complications Rescue  
analgesia 
0min        
4hr        
8hr        
12hr        
16hr        
20hr        
24hr        
Four Point Sedation Score:    1. Asleep, not arousable by verbal contact.  
                                                     2. Sleep, arousable by verbal contact.  
                                                    3. Drowsy not sleeping.   4. Alert/ awake. 
Modified Bromage Scale:                Bromage 0- Patient is able to move the hip, knee and ankle.  
      Bromage 1- Patient is unable to move the hip but able to move the knee and ankle. 
     Bromage 2 - Patient is unable to move the hip and knee but able to move the ankle.  
                                                             Bromage 3 - Patient is unable to move the hip, knee and ankle 
Observation Pain Scale 
HR 
       >10% to < 20% ofpreoperative   
20% to 30% of preoperative level 
 >30% of preoperative level 
0 
1 
2 
BP 
>10% to < 20% of preoperative level  
20 % to 30% of preoperative level  
>30% of preoperative level 
0 
1 
2 
CRYING 
Not crying  
Crying but responds to tender loving care  
Crying and does not respond to tender loving care 
0 
1 
2 
 
  
                                                                                                                                                                                          
LIST OF ABBREVIATIONS  USED 
ASA  -  American Society of Anaesthesiologist 
BP  -  Blood Pressure  
CNS  -  Central Nervous System  
CVS  -  Cardio Vascular System  
EA -  Emergence Agitation  
ED  -  Emergence Delirium  
FDA  - Food and Drug Administration  
FLACC  -  Faces Leg Activity Cry Consolability 
GABA -  Gamma Amino Butyric Acid  
HR -  Heart Rate  
ICU -  Intensive Care Unit  
IV  -  Intra Venous  
MAC  -  Monitored Anaesthesia Care  
MAP  -  Mean Arterial Pressure  
mic/kg/hr - microgram/kilogram body weight/hour  
µg/kg  - microgram/kilogram body weight  
mg/ml  -  milligram/ millilitre 
ml/sec -  millilitre/ second  
NE  -  Nor Epinephrine  
N2O -  Nitrous Oxide  
O2 -  Oxygen  
PACU -  Post Anaesthesia Care Unit  
PONV  - Post Operative Nausea and Vomiting  
SD  -  Standard Deviation  
SE  -  Standard Error  
SpO2  -  Arterial O2 Saturation  
Vd -  Volume of distribution 
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